# DAFTAR PUSTAKA


Agung Mappatanga, M.N., Sirajuddin, J., Eka, H., 2023. VITAMIN D SUPPLEMENTATION IN DRY EYE DISEASE: A SYSTEMATIC REVIEW. Journal of Population and Therapeutics and Clinical Pharmacology. https://doi.org/10.53555/jptcp.v30i19.3817

Alexander, T., Cahyaningsih, E., 2022. The potential role of vitamin D supplementation in the treatment of Dry Eye Disease (DED): a systematic review. Intisari Sains Medis 13, 307–314. https://doi.org/10.15562/ism.v13i1.1250

Alsalem, J.A., Patel, D., Susarla, R., Coca-Prados, M., Bland, R., Walker, E.A., Rauz, S., Wallace, G.R., 2014. Characterization of Vitamin D Production by Human Ocular Barrier Cells. Investigative Opthalmology & Visual Science 55, 2140. https://doi.org/10.1167/iovs.13-13019

Alshahrani, F., Aljohani, N., 2013. Vitamin D: Deficiency, Sufficiency and Toxicity. Nutrients 5, 3605–3616. https://doi.org/10.3390/nu5093605

Ang, B.C.H., Sng, J.J., Wang, P.X.H., Htoon, H.M., Tong, L.H.T., 2017. Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. Sci Rep 7. https://doi.org/10.1038/S41598-017-08534-5

Aranow, C., 2011. Vitamin D and the Immune System. Journal of Investigative Medicine 59, 881–886. https://doi.org/10.2310/JIM.0b013e31821b8755

Armas, L.A.G., Hollis, B.W., Heaney, R.P., 2004. Vitamin D2 Is Much Less Effective than Vitamin D3 in Humans. J Clin Endocrinol Metab 89, 5387–5391. https://doi.org/10.1210/JC.2004-0360

Asyari, F., Winarto, Sjamsoe, S., Triwibowo, A., Sitompul, R., 2019. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN DRY EYE.

Autier, P., Boniol, M., Pizot, C., Mullie, P., 2014. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2, 76–89. https://doi.org/10.1016/S2213-8587(13)70165-7

Bae, S.H., Shin, Y.J., Kim, H.K., Hyon, J.Y., Wee, W.R., Park, S.G., 2016. Vitamin D Supplementation for Patients with Dry Eye Syndrome Refractory to Conventional Treatment. Sci Rep 6. https://doi.org/10.1038/srep33083

Be, K., Özer, P.A., Aydinli, M.S., 2015. The association of vitamin D deficiency with tear break-up time and Schirmer testing in non-Sjögren dry eye. Eye 29, 1081–1084. https://doi.org/10.1038/eye.2015.96

Begley, C.G., Himebaugh, N., Renner, D., Liu, H., Chalmers, R., Simpson, T., Varikooty, J., 2006. Tear breakup dynamics: a technique for quantifying tear film instability. Optom Vis Sci 83, 15–21. https://doi.org/10.1097/01.OPX.0000195569.36185.FD

Benelli, U., Nardi, M., Posarelli, C., Albert, T.G., 2010. Tear osmolarity measurement using the TearLab™ Osmolarity System in the assessment of dry eye treatment effectiveness. Contact Lens and Anterior Eye 33, 61–67. https://doi.org/10.1016/j.clae.2010.01.003

Bicas, H.E.A., 2018. The Arquivos Brasileiros de Oftalmologia and I. Arq Bras Oftalmol 81. https://doi.org/10.5935/0004-2749.20180020

Bikle, D.D., 2014. Vitamin D metabolism, mechanism of action, and clinical [illegible]ons. Chem Biol 21, 319–329. [illegible]i.org/10.1016/J.CHEMBIOL.2013.12.016

Bilezikian, J.P., Formenti, A.M., Adler, R.A., Binkley, N., Bouillon, R., Lazaretti-Castro, M., Marcocci, C., Napoli, N., Rizzoli, R., Giustina, A., 2021. Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? Reviews in Endocrine and Metabolic Disorders 2021 22:4 22, 1201–1218. https://doi.org/10.1007/S11154-021-09693-7

Bowling, B., 2016. Kanski's Clinical Ophthalmology, Eighth Edition (2016). https://doi.org/10.1016/B978-0-7020-5572-0.00025-8

Bron, A.J., de Paiva, C.S., Chauhan, S.K., Bonini, S., Gabison, E.E., Jain, S., Knop, E., Markoulli, M., Ogawa, Y., Perez, V., Uchino, Y., Yokoi, N., Zoukhri, D., Sullivan, D.A., 2017. TFOS DEWS II pathophysiology report. Ocul Surf 15, 438–510. https://doi.org/10.1016/j.jtos.2017.05.011

Bron, A.J., Evans, V.E., Smith, J.A., 2003. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22, 640–650. https://doi.org/10.1097/00003226-200310000-00008

Calcium, I. of M. (US) C. to R.D.R.I. for V.D. and, Ross, A.C., Taylor, C.L., Yaktine, A.L., Valle, H.B. Del, 2011. Dietary Reference Intakes for Adequacy: Calcium and Vitamin D.

Carlson, E., Kao, W.W.Y., Ogundele, A., 2018. Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model. Journal of Ocular Pharmacology and Therapeutics 34, 360. https://doi.org/10.1089/JOP.2017.0080

Chen, Y., Zhang, J., Ge, X., Du, J., Deb, D.K., Li, Y.C., 2013. Vitamin D Receptor Inhibits Nuclear Factor κB Activation by Interacting with IκB Kinase β Protein. f Biological Chemistry 288, 19450–19458. i.org/10.1074/jbc.M113.467670

Condon, P.I., McEwen, C.G., Wright, M., Mackintosh, G., Prescott, R.J., McDonald, C., 1999. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. British Journal of Ophthalmology 83, 1121–1124. https://doi.org/10.1136/bjo.83.10.1121

Craig, J.P., Nelson, J.D., Azar, D.T., Belmonte, C., Bron, A.J., Chauhan, S.K., de Paiva, C.S., Gomes, J.A.P., Hammitt, K.M., Jones, L., Nichols, J.J., Nichols, K.K., Novack, G.D., Stapleton, F.J., Willcox, M.D.P., Wolffsohn, J.S., Sullivan, D.A., 2017a. TFOS DEWS II Report Executive Summary. Ocular Surface. https://doi.org/10.1016/j.jtos.2017.08.003

Craig, J.P., Nichols, K.K., Akpek, E.K., Caffery, B., Dua, H.S., Joo, C.K., Liu, Z., Nelson, J.D., Nichols, J.J., Tsubota, K., Stapleton, F., 2017b. TFOS DEWS II Definition and Classification Report. Ocular Surface 15, 276–283. https://doi.org/10.1016/J.JTOS.2017.05.008

Dana, R., Bradley, J.L., Guerin, A., Pivneva, I., Stillman, I.Ö., Evans, A.M., Schaumberg, D.A., 2019. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am J Ophthalmol 202, 47–54. https://doi.org/10.1016/j.ajo.2019.01.026

Dawson-Hughes, B., Harris, S.S., Lichtenstein, A.H., Dolnikowski, G., Palermo, N.J., Rasmussen, H., 2015. Dietary fat increases vitamin d-3 absorption. J Acad Nutr Diet 115, 225–230. https://doi.org/10.1016/j.jand.2014.09.014

Demirci, G., Karaman Erdur, S., Ozsutcu, M., Eliacik, M., Olmuscelik, O., Aydin, R., [illegible], M.S., 2018. Dry Eye Assessment in Patients With Vitamin D [illegible]cy. Eye & Contact Lens: Science & Clinical Practice 44, S62–S65. [illegible]i.org/10.1097/ICL.0000000000000325

DEWS, 2007. DEWS (2007) The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007).

Elizondo, R.A., Yin, Z., Lu, X., Watsky, M.A., 2014. Effect of Vitamin D Receptor Knockout on Cornea Epithelium Wound Healing and Tight Junctions. Investigative Opthalmology & Visual Science 55, 5245. https://doi.org/10.1167/iovs.13-13553

Farrand, K.F., Fridman, M., Stillman, I.Ö., Schaumberg, D.A., 2017. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol 182, 90–98. https://doi.org/10.1016/j.ajo.2017.06.033

Feder, R.S., 2021. 2021-2022 Basic and Clinical Science Course, Section 8: External Disease and Cornea.

Feder, R.S., Berdy, G.J., Iuorno, J.D., Marcovich, A.L., Mian, S.I., Reilly, C.D., Trief, D., Verdier, D.D., 2022. BCSC ® Basic and Clinical Science Course ™ Editorial Committee External Disease and Cornea 8.

Fogagnolo, P., De Cilla', S., Alkabes, M., Sabella, P., Rossetti, L., 2021. A Review of Topical and Systemic Vitamin Supplementation in Ocular Surface Diseases. Nutrients 13, 1998. https://doi.org/10.3390/nu13061998

Giustina, A., Adler, R.A., Binkley, N., Bollerslev, J., Bouillon, R., Dawson-Hughes, B., Ebeling, P.R., Feldman, D., Formenti, A.M., Lazaretti-Castro, M., Marcocci, C., Rizzoli, R., Sempos, C.T., Bilezikian, J.P., 2020. Consensus statement from national Conference on Controversies in Vitamin D. Reviews in e and Metabolic Disorders 2020 21:1 21, 89–116. i.org/10.1007/S11154-019-09532-W

Giustina, Andrea, Bouillon, R., Binkley, N., Sempos, C., Adler, R.A., Bollerslev, J., Dawson-Hughes, B., Ebeling, P.R., Feldman, D., Heijboer, A., Jones, G., Kovacs, C.S., Lazaretti-Castro, M., Lips, P., Marcocci, C., Minisola, S., Napoli, N., Rizzoli, R., Scragg, R., White, J.H., Formenti, A.M., Bilezikian, J.P., 2020. Controversies in Vitamin D: A Statement From the Third International Conference. JBMR Plus 4, e10417. https://doi.org/10.1002/JBM4.10417

Gomes, J.A.P., Azar, D.T., Baudouin, C., Efron, N., Hirayama, M., Horwath-Winter, J., Kim, T., Mehta, J.S., Messmer, E.M., Pepose, J.S., Sangwan, V.S., Weiner, A.L., Wilson, S.E., Wolffsohn, J.S., 2017. TFOS DEWS II iatrogenic report. Ocul Surf 15, 511–538. https://doi.org/10.1016/j.jtos.2017.05.004

Goncalves, A., Gleize, B., Bott, R., Nowicki, M., Amiot, M.J., Lairon, D., Borel, P., Reboul, E., 2011. Phytosterols can impair vitamin D intestinal absorption in vitro and in mice. Mol Nutr Food Res 55, S303–S311. https://doi.org/10.1002/MNFR.201100055

Goncalves, A., Gleize, B., Roi, S., Nowicki, M., Dhaussy, A., Huertas, A., Amiot, M.J., Reboul, E., 2013. Fatty acids affect micellar properties and modulate vitamin D uptake and basolateral efflux in Caco-2 cells. J Nutr Biochem 24, 1751–1757. https://doi.org/10.1016/J.JNUTBIO.2013.03.004

Hallak, J.A., Tibrewal, S., Mohindra, N., Gao, X., Jain, S., 2015. Single Nucleotide Polymorphisms in the BDNF, VDR, and DNASE 1 Genes in Dry Eye Disease Patients: A Case-Control Study. Investigative Opthalmology & Visual Science 56, 5990. https://doi.org/10.1167/iovs.15-17036

ri, A., Syawal, R., Sirajuddin, J., Asy'ari, A.H., Ilmu, B., Mata, K., JBUNGAN SENSITIVITAS KORNEA DENGAN DERAJAT DRY ɔA PASIEN DIABETES MELITUS TIPE 2 THE CORRELATION

BETWEEN CORNEAL SENSITIVITY AND THE DEGREE OF DRY EYE IN TYPE 2 DIABETIC MELLITUS PATIENTS. Bagian Ilmu Kesehatan Mata Fakultas Kedokteran 1–2.

Heaney, R.P., 2014. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 72, 48–54. https://doi.org/10.1111/nure.12090

Holick, M.F., 2009. VITAMIN D STATUS: MEASUREMENT, INTERPRETATION AND CLINICAL APPLICATION. Ann Epidemiol 19, 73. https://doi.org/10.1016/J.ANNEPIDEM.2007.12.001

Holick, M.F., 2004. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79, 362–371. https://doi.org/10.1093/ajcn/79.3.362

Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H., Weaver, C.M., 2011. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96, 1911–1930. https://doi.org/10.1210/jc.2011-0385

Hwang, J.S., Lee, Y.P., Shin, Y.J., 2019. Vitamin D enhances the efficacy of topical artificial tears in patients with dry eye disease. Cornea 38, 304–310. https://doi.org/10.1097/ICO.0000000000001822

Jain, N., Sharma, P., Chouhan, J., 2022. A study of the association between Vitamin D deficiency and Dry Eye Syndrome (DES) in the Indian population. Indian J Ophthalmol 70, 500. https://doi.org/10.4103/ijo.IJO_1921_21

[redacted]eom, H., Yang, J., Song, J.S., Lee, H.K., Kim, H.C., 2017. Are Serum D Levels Associated With Dry Eye Disease? Results From the Study

Group for Environmental Eye Disease. Journal of Preventive Medicine and Public Health 50, 369–376. https://doi.org/10.3961/jpmph.17.089

Jin, K.W., Ro, J.W., Shin, Y.J., Hyon, J.Y., Wee, W.R., Park, S.G., 2017. Correlation of vitamin D levels with tear film stability and secretion in patients with dry eye syndrome. Acta Ophthalmol 95, e230–e235. https://doi.org/10.1111/AOS.13241

Johnson, J.A., Grande, J.P., Roche, P.C., Campbell, R.J., Kumar, R., 1995. Immuno-localization of the calcitriol receptor, calbinclin-D $_{28k}$ and the plasma membrane calcium pump in the human eye. Curr Eye Res 14, 101–108. https://doi.org/10.3109/02713689508999921

Johnson, M.E., Murphy, P.J., Boulton, M., 2006. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefe's Archive for Clinical and Experimental Ophthalmology 244, 109–112. https://doi.org/10.1007/s00417-005-0028-1

Jones, L., Downie, L.E., Korb, D., Benitez-del-Castillo, J.M., Dana, R., Deng, S.X., Dong, P.N., Geerling, G., Hida, R.Y., Liu, Y., Seo, K.Y., Tauber, J., Wakamatsu, T.H., Xu, J., Wolffsohn, J.S., Craig, J.P., 2017. TFOS DEWS II Management and Therapy Report. Ocul Surf 15, 575–628. https://doi.org/10.1016/j.jtos.2017.05.006

Karaca, E.E., Kemer, Ö.E., Özek, D., Berker, D., Imga, N.N., 2020. Clinical outcomes of ocular surface in patients treated with vitamin D oral replacement. Arq Bras Oftalmol 83. https://doi.org/10.5935/0004-2749.20200043

Kempen, J.H., Daniel, E., Gangaputra, S., Dreger, K., Jabs, D.A., Kaçmaz, R.O., S., Anzaar, F., Foster, C.S., Helzlsouer, K.J., Levy-Clarke, G.A., att, R.B., Liesegang, T., Rosenbaum, J.T., Suhler, E.B., 2009. Methods fying Long-Term Adverse Effects of Treatment in Patients with Eye

Diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. http://dx.doi.org/10.1080/09286580701585892 15, 47–55. https://doi.org/10.1080/09286580701585892

Kempen, J.H., Daniel, E., Gangaputra, S., Dreger, K., Jabs, D.A., Kaçmaz, R.O., Pujari, S.S., Anzaar, F., Foster, C.S., Helzlsouer, K.J., Levy-Clarke, G.A., Nussenblatt, R.B., Liesegang, T., Rosenbaum, J.T., Suhler, E.B., 2008. Methods for Identifying Long-Term Adverse Effects of Treatment in Patients with Eye Diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15, 47–55. https://doi.org/10.1080/09286580701585892

Khamar, P., Nair, A.P., Shetty, R., Vaidya, T., Subramani, M., Ponnalagu, M., Dhamodaran, K., D'souza, S., Ghosh, Anuprita, Pahuja, N., Deshmukh, R., Ahuja, P., Sainani, K., Nuijts, R.M.M.A., Das, D., Ghosh, Arkasubhra, Sethu, S., 2019. Dysregulated Tear Fluid Nociception-Associated Factors, Corneal Dendritic Cell Density, and Vitamin D Levels in Evaporative Dry Eye. Investigative Opthalmology & Visual Science 60, 2532. https://doi.org/10.1167/iovs.19-26914

Khanal, S., Tomlinson, A., Esakowitz, L., Bhatt, P., Jones, D., Nabili, S., Mukerji, S., 2008. Changes in corneal sensitivity and tear physiology after phacoemulsification. Ophthalmic and Physiological Optics 28, 127–134. https://doi.org/10.1111/j.1475-1313.2008.00539.x

Kim, H., An, Y., Hwang, W.J., 2023. Gender differences in dry eye disease symptoms d with psychological health indicators among adults using mobile ealth apps. PLoS One 18. i.org/10.1371/JOURNAL.PONE.0278921

Kim, M.J., Hwang, H.R., Kim, Y.-J., Lee, S.-Y., Lee, J.-G., Jeong, D.-W., Kim, Y.H., 2017. Association Between Serum 25-Hydroxyvitamin D Levels and Dry Eye in Korean Adults: A Study Based on Korean National Health and Nutrition Examination Survey, 2010–2011. Korean J Fam Med 38, 81. https://doi.org/10.4082/kjfm.2017.38.2.81

Kizilgul, M., Kan, S., Ozcelik, O., Beysel, S., Apaydin, M., Ucan, B., Cakal, E., 2017. Vitamin D Replacement Improves Tear Osmolarity in Patients with Vitamin D Deficiency. https://doi.org/10.1080/08820538.2017.1358752 33, 589–594. https://doi.org/10.1080/08820538.2017.1358752

Kojima, T., Nagata, T., Kudo, H., Müller-Lierheim, W.G.K., Setten, G.B. van, Dogru, M., Tsubota, K., 2020. The Effects of High Molecular Weight Hyaluronic Acid Eye Drop Application in Environmental Dry Eye Stress Model Mice. International Journal of Molecular Sciences 2020, Vol. 21, Page 3516 21, 3516. https://doi.org/10.3390/IJMS21103516

Kopacz, D., Niezgoda, Ł., Fudalej, E., Nowak, A., Maciejewicz, P., 2021. Tear Film – Physiology and Disturbances in Various Diseases and Disorders, in: Ocular Surface Diseases - Some Current Date on Tear Film Problem and Keratoconic Diagnosis. IntechOpen. https://doi.org/10.5772/intechopen.94142

Labetoulle, M., Benitez-del-Castillo, J.M., Barabino, S., Herrero Vanrell, R., Daull, P., Garrigue, J.-S., Rolando, M., 2022. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int J Mol Sci 23, 2434. https://doi.org/10.3390/ijms23052434

quinho, R.G., Perez, M.M., Alves, B. da C.A., Pereira, E.C., Azzalis, queira, V.B.C., Soares, L.R., Fonseca, F.L.A., 2019. Determination of

vitamin D in tears of healthy individuals by the electrochemiluminescence method. J Clin Lab Anal 33, e22830. https://doi.org/10.1002/jcla.22830

Lee, A.J., Lee, J., Saw, S.M., Gazzard, G., Koh, D., Widjaja, D., Tan, D.T.H., 2002. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol 86, 1347. https://doi.org/10.1136/BJO.86.12.1347

Lee, J.H., Ahn, H.S., Kim, E.K., Kim, T.I., 2011. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 30, 175–179. https://doi.org/10.1097/ICO.0B013E3181E9ADCC

Lee, V., Rekhi, E., Hoh Kam, J., Jeffery, G., 2012. Vitamin D rejuvenates aging eyes by reducing inflammation, clearing amyloid beta and improving visual function. Neurobiol Aging 33, 2382–2389. https://doi.org/10.1016/j.neurobiolaging.2011.12.002

Lemp, M.A., Baudouin, C., Baum, J., Dogru, M., Foulks, G.N., Kinoshita, S., Laibson, P., McCulley, J., Murube, J., Pflugfelder, S.C., Rolando, M., Toda, I., 2007. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 5, 75–92. https://doi.org/10.1016/S1542-0124(12)70081-2

Lin, Y., Su, H., Wu, J., Yuan, M., Zhang, Y., 2022a. Oral vitamin D3 supplementation for femtosecond LASIK-associated dry eye vitamin D for LASIK dry eye syndrome. Int Ophthalmol 42, 3145–3152. https://doi.org/10.1007/s10792-022-02314-5

., Wu, J., Yuan, M., Zhang, Y., 2022b. Oral vitamin D3 ntation for femtosecond LASIK-associated dry eye vitamin D for

LASIK dry eye syndrome. Int Ophthalmol 42, 3145–3152. https://doi.org/10.1007/s10792-022-02314-5

Lin, Y., Ubels, J.L., Schotanus, M.P., Yin, Z., Pintea, V., Hammock, B.D., Watsky, M.A., 2012. Enhancement of Vitamin D Metabolites in the Eye Following Vitamin D3 Supplementation and UV-B Irradiation. Curr Eye Res 37, 871–878. https://doi.org/10.3109/02713683.2012.688235

Liu, H., Begley, C., Chen, M., Bradley, A., Bonanno, J., McNamara, N.A., Nelson, J.D., Simpson, T., 2009. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci 50, 3671–3679. https://doi.org/10.1167/IOVS.08-2689

Liu, J., Dong, Y., Wang, Y., 2020. Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. Acta Ophthalmol 98, 749–754. https://doi.org/10.1111/aos.14470

Lu, X., Chen, Z., Mylarapu, N., Watsky, M.A., 2017. Effects of 1,25 and 24,25 Vitamin D on Corneal Epithelial Proliferation, Migration and Vitamin D Metabolizing and Catabolizing Enzymes. Sci Rep 7, 16951. https://doi.org/10.1038/s41598-017-16698-3

Luo, L., Li, D.-Q., Doshi, A., Farley, W., Corrales, R.M., Pflugfelder, S.C., 2004. Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular Surface. Investigative Opthalmology & Visual Science 45, 4293. https://doi.org/10.1167/iovs.03-1145

[redacted], 2014. Diagnosis and Treatment Methods for Ocular Surface Disease in [redacted]a. European Ophthalmic Review 08, 40. [redacted]i.org/10.17925/EOR.2014.08.01.40

Meng, Y.F., Lu, J., Xing, Q., Tao, J.J., Xiao, P., 2017. Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome. Medical Science Monitor 23, 2211–2216. https://doi.org/10.12659/MSM.901857

Messmer, E.M., 2015. The Pathophysiology, Diagnosis, and Treatment of Dry Eye Disease. Dtsch Arztebl Int. https://doi.org/10.3238/arztebl.2015.0071

Messmer, E.M., Hoops, J.P., Kampik, A., 2005. Bilateral Recurrent Calcareous Degeneration of the Cornea. Cornea 24, 498–502. https://doi.org/10.1097/01.ico.0000151559.32613.0b

Miller, K.L., Walt, J.G., Mink, D.R., Satram-Hoang, S., Wilson, S.E., Perry, H.D., Asbell, P.A., Pflugfelder, S.C., 2010. SOCIOECONOMICS AND HEALTH SERVICES Minimal Clinically Important Difference for the Ocular Surface Disease Index, Arch Ophthalmol.

Muehleisen, B., Gallo, R.L., 2013. Vitamin D in allergic disease: Shedding light on a complex problem. Journal of Allergy and Clinical Immunology 131, 324–329. https://doi.org/10.1016/j.jaci.2012.12.1562

Muñoz-Villegas, P., Sánchez-Ríos, A., Olvera-Montaño, O., 2023. The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease. Clinical Ophthalmology Volume 17, 2945–2955. https://doi.org/10.2147/OPTH.S433709

Najjaran, M., Zarei- Ghanavati, S., Arjmand Askari, E., Eslampoor, A., Ziaei, M., 2023. Effect of oral vitamin D supplementation on dry eye disease patients with vitamin D deficiency. Clin Exp Optom 106, 257–262. [illegible]i.org/10.1080/08164622.2022.2033601

[illegible]., Shakila, A., Meliani, M., Halim, A., 2023. Vitamin D deficiency is a [illegible]alth emergency among Indonesian children and adolescents: a

systematic review and meta-analysis of prevalence. Ann Pediatr Endocrinol Metab 28, 10–19. https://doi.org/10.6065/apem.2244170.085

Okumura, Y., Inomata, T., Iwata, N., Sung, J., Fujimoto, K., Fujio, K., Midorikawa-Inomata, A., Miura, M., Akasaki, Y., Murakami, A., 2020. A Review of Dry Eye Questionnaires: Measuring Patient-Reported Outcomes and Health-Related Quality of Life. Diagnostics 10, 559. https://doi.org/10.3390/diagnostics10080559

Oncul, H., Alakus, M., Caglayan, M., Oncul, F., Dag, U., Arac, E., 2020. Impact of vitamin D supplementation on the ocular surface in patients with vitamin d deficiency. Ann Med Res 27, 2726. https://doi.org/10.5455/annalsmedres.2020.04.392

Ota, K., Dambaeva, S., Kim, M.W. Il, Han, A.R., Fukui, A., Gilman-Sachs, A., Beaman, K., Kwak-Kim, J., 2015. 1,25-Dihydroxy-vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion, and degranulation in women with recurrent pregnancy losses. Eur J Immunol 45, 3188–3199. https://doi.org/10.1002/EJI.201545541

Papas, E.B., 2021. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic and Physiological Optics 41, 1254–1266. https://doi.org/10.1111/OPO.12888

Paul, C., Veldhuisen, V., Fred, E.M., 2000. The Advanced Glaucoma Intervention Study (AGIS): 7. The Relationship Between Control of Intraocular Pressure and Visual Field Deterioration.

cinini, P., Carta, F., 2007. Effect of oral linoleic and gamma-linolenic meibomian gland dysfunction. Cornea 26, 260–264. i.org/10.1097/ICO.0B013E318033D79B

Raimundo, F.V., Lang, M.A.B., Scopel, L., Marcondes, N.A., Araújo, M.G.A., Faulhaber, G.A.M., Furlanetto, T.W., 2015. Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study. Eur J Nutr 54, 391–396. https://doi.org/10.1007/S00394-014-0718-8/METRICS

Raymond, E., Dalgleish, A., Damber, J.E., Smith, M., Pili, R., 2014. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 73, 1–8. https://doi.org/10.1007/S00280-013-2321-8/FIGURES/1

Reboul, E., Goncalves, A., Comera, C., Bott, R., Nowicki, M., Landrier, J.F., Jourdheuil-Rahmani, D., Dufour, C., Collet, X., Borel, P., 2011. Vitamin D intestinal absorption is not a simple passive diffusion: Evidences for involvement of cholesterol transporters. Mol Nutr Food Res 55, 691–702. https://doi.org/10.1002/MNFR.201000553

Reins, R.Y., Baidouri, H., McDermott, A.M., 2015. Vitamin D Activation and Function in Human Corneal Epithelial Cells During TLR-Induced Inflammation. Investigative Opthalmology & Visual Science 56, 7715. https://doi.org/10.1167/iovs.15-17768

Reins, R.Y., Hanlon, S.D., Magadi, S., McDermott, A.M., 2016. Effects of Topically Applied Vitamin D during Corneal Wound Healing. PLoS One 11, e0152889. https://doi.org/10.1371/journal.pone.0152889

Rolando, M., Barabino, S., 2023. Dry Eye Disease: What Is the Role of Vitamin D? Int J Mol Sci 24, 1458. https://doi.org/10.3390/ijms24021458

Borsook, D., 2016. Ocular neuropathic pain. Br J Ophthalmol 100, https://doi.org/10.1136/BJOPHTHALMOL-2014-306280

Schiffman, R.M., Christianson, M.D., Jacobsen, G., Hirsch, J.D., Reis, B.L., 2000. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 118, 615–621. https://doi.org/10.1001/ARCHOPHT.118.5.615

Sethu, S., Shetty, R., Deshpande, K., Pahuja, N., Chinnappaiah, N., Agarwal, A., Sharma, A., Ghosh, A., 2016. Correlation between tear fluid and serum vitamin D levels. Eye and Vision 3, 22. https://doi.org/10.1186/s40662-016-0053-7

Shetty, R., Sethu, S., Chevour, P., Deshpande, K., Pahuja, N., Nagaraja, H., Pindipapanahalli, N., Ghosh, A., 2016. Lower Vitamin D Level and Distinct Tear Cytokine Profile Were Observed in Patients with Mild Dry Eye Signs but Exaggerated Symptoms. Transl Vis Sci Technol 5, 16. https://doi.org/10.1167/tvst.5.6.16

Shimazaki, J., 2018. Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions. Invest Ophthalmol Vis Sci 59, DES7–DES12. https://doi.org/10.1167/IOVS.17-23475

Shipton, E.E., Shipton, E.A., 2015. Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States. Pain Ther 4, 67–87. https://doi.org/10.1007/S40122-015-0036-8

Silva, M.C., Furlanetto, T.W., 2018. Intestinal absorption of vitamin D: a systematic review. Nutr Rev 76, 60–76. https://doi.org/10.1093/NUTRIT/NUX034

Singman, E.L., Poon, D., Jun, A.S., 2013. Putative corneal neuralgia responding to vitamin d supplementation. Case Rep Ophthalmol 4, 105–108. https://doi.org/10.1159/000354965

Pawlicka, I., Gil, K., 2018. Th e role of vitamin D in the pathogenesis diseases. Folia Med Cracov LVIII, 103–108.

Stapleton, F., Alves, M., Bunya, V.Y., Jalbert, I., Lekhanont, K., Malet, F., Na, K.-S., Schaumberg, D., Uchino, M., Vehof, J., Viso, E., Vitale, S., Jones, L., 2017. TFOS DEWS II Epidemiology Report. Ocul Surf 15, 334–365. https://doi.org/10.1016/j.jtos.2017.05.003

Starr, C.E., Winebrake, J.P., Drinkwater, O.J., Brissette, A.R., Fekrat, S., Scott, I.U., 2017. E Y E N E T M A G A Z I N E • 63 The TFOS Dry Eye Workshop II: Key Updates Epidemiology 3 Wide-ranging estimates. Assessment of large-scale DED prevalence and in-cidence has been hindered by inconsis-tencies in the definition and diagnostic.

Stuff, M., 2016. Vitamin D Metabolism [WWW Document]. Printerest. URL https://pin.it/3MVhz8c (accessed 6.3.23).

Sugiyono, Nuryanto, A., 2007. Statistika untuk Penelitian. Alfabeta, Bandung.

Suzuki, T, Sano, Y., Kinoshita, S., 2000. Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice. Invest Ophthalmol Vis Sci 41, 154–8.

Suzuki, Tomo, Sano, Y., Sotozono, C., Kinoshita, S., 2000. Regulatory effects of 1a,25-dihydroxyvitamin D3 on cytokine production by human corneal epithelial cells. Curr Eye Res 20, 127–130. https://doi.org/10.1076/0271-3683(200002)2021-DFT127

Tomlinson, A., Bron, A.J., Korb, D.R., Amano, S., Paugh, J.R., Ian Pearce, E., Yee, R., Yokoi, N., Arita, R., Dogru, M., 2011. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 52, 2006–2049. https://doi.org/10.1167/IOVS.10-6997F

. W., Petznick, A., 2012. Definition of the Ocular Surface, in: Ocular CRC Press, pp. 3–21. https://doi.org/10.1201/b13153-3

Toniato, E., Spinas, E., Saggini, A., Kritas, S.K., Caraffa, A., Antinolfi, P., Saggini, R., Pandolfi, F., Conti, P., 2015. IMMUNOMODULATORY EFFECTS OF VITAMIN D ON SKIN INFLAMMATION. J Biol Regul Homeost Agents 29, 563–7.

von Känel, R., Müller-Hartmannsgruber, V., Kokinogenis, G., Egloff, N., 2014. Vitamin D and central hypersensitivity in patients with chronic pain. Pain Med 15, 1609–1618. https://doi.org/10.1111/PME.12454

Watts, P., Sahai, A., Kumar, P.R., Shamshad, M.A., Trivedi, G.K., Tyagi, L., 2020. A prospective study to assess the role of vitamin D individually and in combination with cyclosporine in the treatment of dry eye in patients with deficient serum 25(OH)D levels. Indian J Ophthalmol 68, 1020–1026. https://doi.org/10.4103/ijo.IJO_1492_19

Willcox, M.D.P., Argüeso, P., Georgiev, G.A., Holopainen, J.M., Laurie, G.W., Millar, T.J., Papas, E.B., Rolland, J.P., Schmidt, T.A., Stahl, U., Suarez, T., Subbaraman, L.N., Uçakhan, O., Jones, L., 2017. TFOS DEWS II Tear Film Report. Ocul Surf 15, 366. https://doi.org/10.1016/J.JTOS.2017.03.006

Wolffsohn, J.S., Arita, R., Chalmers, R., Djalilian, A., Dogru, M., Dumbleton, K., Gupta, P.K., Karpecki, P., Lazreg, S., Pult, H., Sullivan, B.D., Tomlinson, A., Tong, L., Villani, E., Yoon, K.C., Jones, L., Craig, J.P., 2017. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 15, 539–574. https://doi.org/10.1016/j.jtos.2017.05.001

Yang, C.H., Albietz, J., Harkin, D.G., Kimlin, M.G., Schmid, K.L., 2018. Impact of ɪin D supplementation on the ocular surface in people with dry eye w serum vitamin D. Contact Lens and Anterior Eye 41, 69–76. ı.org/10.1016/j.clae.2017.09.007

Yang, G., Wang, Y.M., 2021. Effects of M2 Polarization of Microglia on Inflammatory Injury in Cerebral Haemorrhage. Indian J Pharm Sci 83.

Yang, Y.-J., Lee, W.-Y., Kim, Y., Hong, Y., 2021. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. Int J Environ Res Public Health 18, 2383. https://doi.org/10.3390/ijerph18052383

Yang, Y.J., Lee, W.Y., Kim, Y.J., Hong, Y.P., 2021. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. International Journal of Environmental Research and Public Health 2021, Vol. 18, Page 2383 18, 2383. https://doi.org/10.3390/IJERPH18052383

Yildirim, P., Garip, Y., Karci, A.A., Guler, T., 2016. Dry eye in vitamin D deficiency: more than an incidental association. Int J Rheum Dis 19, 49–54. https://doi.org/10.1111/1756-185X.12727

Yin, Z., Pintea, V., Lin, Y., Hammock, B.D., Watsky, M.A., 2011. Vitamin D Enhances Corneal Epithelial Barrier Function. Investigative Opthalmology & Visual Science 52, 7359. https://doi.org/10.1167/iovs.11-7605

Yoon, S.Y., Bae, S.H., Shin, Y.J., Park, S.G., Hwang, S.-H., Hyon, J.Y., Wee, W.R., 2016. Low Serum 25-Hydroxyvitamin D Levels Are Associated with Dry Eye Syndrome. PLoS One 11, e0147847. https://doi.org/10.1371/journal.pone.0147847

Zaky, M.A., Marey, H.M., Elmonem, D.G.H.A., Fayed, A.M.S., 2022. Effect of vitamin D on the efficacy of topical artificial tears in patients with dry-eye disease. Menoufia Medical Journal 35, 856.

[illegible]i.org/10.4103/MMJ.MMJ_245_21

[illegible]ı, H., Liu, L., Li, H., Shih, D.Q., Zhang, X., 2015. 1,25-

[illegible]yvitamin D3 regulates the development of chronic colitis by modulating

both T helper (Th)1 and Th17 activation. APMIS 123, 490–501. https://doi.org/10.1111/APM.12378

Zhang, J., Dai, Y., Wu, D., Xu, J., 2019. Calcitriol, the Active Metabolite of Vitamin D $_3$ , Inhibits Dry Eye Related Corneal Inflammation *In Vivo* and *In Vitro*. Ocul Immunol Inflamm 27, 257–265. https://doi.org/10.1080/09273948.2017.1372486

Zhang, R., Naughton, D.P., 2010. Vitamin D in health and disease: Current perspectives. Nutr J 9, 65. https://doi.org/10.1186/1475-2891-9-65

Zhou, L., Wang, J., Li, J., Li, T., Chen, Y., June, R.R., Zheng, S.G., 2019. 1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through miR-124 Mediated Inhibition of IL-6 Signaling. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.00178

## LAMPIRAN 1: REKOMENDASI PERSETUJUAN ETIK

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD. SpGK. TELP. 081241850858, 0411 5780103. Fax : 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**
Nomor : 562/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 14 Agustus 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---|---|---|---|
| No Protokol | UH23060415 | No Sponsor | |
| Peneliti Utama | **dr. Muhammad Nur Agung Mappatanga** | Sponsor | |
| Judul Peneliti | Evaluasi Klinis Vitamin D3 Oral Dikombinasi Natrium Hialuronat Topikal pada Penderita Dry Eye Disease | | |
| No Versi Protokol | **2** | Tanggal Versi | **8 Agustus 2023** |
| No Versi PSP | **2** | Tanggal Versi | **8 Agustus 2023** |
| Tempat Penelitian | RS Universitas Hasanuddin Makassar | | |
| Jenis Review | ☐ Exempted<br>☒ Expedited<br>☐ Fullboard Tanggal | Masa Berlaku **14 Agustus 2023** sampai **14 Agustus 2024** | Frekuensi review lanjutan |
| Ketua KEP Universitas Hasanuddin | Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)** | Tanda tangan | |
| Sekretaris KEP Universitas Hasanuddin | Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)** | Tanda tangan | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## LAMPIRAN 2: FORMULIR PERSETUJUAN PENELITIAN

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**LAMPIRAN 2**

**FORMULIR PERSETUJUAN SETELAH PENJELASAN**

Saya yang bertandatangan di bawah ini :

Nama : .....
Umur : .....
Masa Kerja : .....
Satuan : .....
Alamat : .....
.....

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

| | **Nama** | **Tanda tangan** | **Tgl/Bln/Thn** |
|---|---|---|---|
| Responden | …….. | …….. | …….. |
| /Wali | | | |
| Saksi | …….. | …….. | …….. |

(Tanda Tangan Saksi diperlukan hanya jika Partisipan tidak dapat memberikan consent/persetujuan sehingga menggunakan wali yang sah secara hukum, yaitu untuk partisipan berikut:

1. Berusia di bawah 18 tahun
2. Usia lanjut
3. Gangguan mental
4. Pasien tidak sadar
5. Dan lain-lain kondisi yang tidak memungkinkan memberikan persetujuan

**Penanggung jawab penelitian :**

dr. Muhammad Nur Agung Mappatanga
Jl. Borong Indah, Perumahan Puri Taman Sari Blok B3 No.15
Telp. 082347675050

**anggung jawab medik :**
dr. Junaedi Sirajuddin, Sp.M(K)
Kompleks Phinisi Residence Blok B5
Telp. 08114130860

DISETUJUI OLEH KOMISI
PENELITIAN KESEHATAN
FAKULTAS KEDOKTERAN UNHAS
TGL……2023

## LAMPIRAN 3: FORM KUESIONER DRY EYE

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
**Contact Person:** dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**LAMPIRAN 10**

**KUESIONER *DRY EYE***

**NAMA:** _____ **RM :** _____

**TGL LAHIR** :_____/_____/_____

**JENIS KELAMIN :** ☐Laki-laki ☐Perempuan

**PEKERJAAN :** ☐ PNS ☐Wiraswasta ☐Lain-lain :_____

**TINGKAT PENDIDIKAN TERAKHIR :**

☐ SD ☐SMP ☐SMA ☐S1 ☐S2 ☐ S3

**SUKU :** _____

**RIWAYAT PENYAKIT SISTEMIK :**

☐ Diabetes Mellitus ☐ Hipertensi ☐ Lain-lain: _____

**Kuesioner *Ocular Surface Disease Index* (OSDI)**

Jawablah 12 pertanyaan berikut dengan melingkari angka di dalam table yang sesuai dengan jawaban anda.

| **Apakah anda mengalami kondisi sebagai berikut dalam 1 minggu terakhir?** | **Selalu sepanjang hari** | **Sebagian besar hari** | **Separuh hari** | **Kadang-kadang** | **Tidak pernah** |
|---|---|---|---|---|---|
| 1. Mata sensitif terhadap cahaya? | 4 | 3 | 2 | 1 | 0 |
| 2. Mata terasa mengganjal atau berpasir? | 4 | 3 | 2 | 1 | 0 |
| 3. Mata terasa nyeri? | 4 | 3 | 2 | 1 | 0 |
| 4. Gangguan penglihatan ringan (penglihatan buram / kabur)?* | 4 | 3 | 2 | 1 | 0 |

| | | | | | |
|---|---|---|---|---|---|
| 5. Gangguan penglihatan berat?* | 4 | 3 | 2 | 1 | 0 |

Keterangan * : Gangguan penglihatan ditentukan menggunakan *reduced snellen eye chart* jarak 35 cm
- Gangguan penglihatan ringan : Jika tajam penglihatan berkisar (20/40-20/60)
- Gangguan penglihatan berat: Jika tajam penglihatan berkisar (3/60-6/60)

Subtotal skor untuk jawaban 1 – 5 (A) ☐

| **Apakah anda memiliki kesulitan dalam melakukan hal-hal sebagai berikut dalam 1 minggu terakhir?** | **Selalu sepanjang hari** | **Sebagian besar hari** | **Separuh hari** | **Kadang-kadang** | **Tidak ada kesulitan** | **Tidak melakukan** |
|---|---|---|---|---|---|---|
| 6. Membaca? | 4 | 3 | 2 | 1 | 0 | N/A |
| 7. Mengendarai kendaraan di malam hari? | 4 | 3 | 2 | 1 | 0 | N/A |
| 8. Bekerja dengan computer atau menggunakan ATM (Anjungan Tunai Mandiri) bank? | 4 | 3 | 2 | 1 | 0 | N/A |
| 9. Menonton televisi? | 4 | 3 | 2 | 1 | 0 | N/A |

Subtotal skor untuk jawaban 6 – 9 (B) ☐

| **Apakah anda pernah mengalami rasa tidak nyaman di mata saat berada pada kondisi sebagai berikut dalam 1 minggu terakhir?** | **Selalu sepanjang hari** | **Sebagian besar hari** | **Separuh hari** | **Kadang-kadang** | **Tidak pernah** | **Tidak melakukan** |
|---|---|---|---|---|---|---|
| 10. Kondisi berangin? | 4 | 3 | 2 | 1 | 0 | N/A |
| 11. Tempat atau ruangan dengan kelembaban rendah (sangat kering)?* | 4 | 3 | 2 | 1 | 0 | N/A |
| 12. Tempat dengan pendingin ruangan? | 4 | 3 | 2 | 1 | 0 | N/A |

Keterangan * : Tempat atau ruangan dengan kelembapan rendah : Kelembapan lingkungan rendah dikaitkan jika sehari-hari tidak menggunakan AC (*air conditioner*).

Subtotal skor untuk jawaban 10 – 12 (C) ☐

Jumlahkan subtotal A, B, dan C untuk mendapat nilai D ☐

**HASIL PEMERIKSAAN MATA**

**NAMA: _____ RM :**

**TGL LAHIR :_____/_____/_____**

Visus Oculus dexter :

Visus Oculus sinister :

**PEMERIKSAAN SLITLAMP**

| **OD** | Slit Lamp | **OS** |
|---|---|---|
| Hiperemis (+); Edema (-); Benjolan (-) | **Palpebra** | Hiperemis (-), Edema (-), Benjolan (-) |
| Injeksi konjungtiva (+); Injeksi siliar (-) ; Sekret Mukoid (-) ; perdarahan (-) | **Konjungtiva / Sklera** | Injeksi konjungtiva (-); Injeksi siliar (-) ; Sekret (-) ; perdarahan (-) |
| Jernih  | **Kornea** | Jernih  |
| Dalam, jernih | **BMD** | Dalam, jernih |
| Coklat, kripte (+), sinekia anterior (-), sinekia posterior (-) | **Iris** | Coklat, kripte (+), sinekia anterior (-), sinekia posterior (-) |
| Bulat, refleks cahaya (+) | **Pupil** | Bulat, refleks cahaya (+) |
| Jernih  | **Lensa** | Jernih  |
| Tidak ada | **Lokasi Kekeruhan** | Tidak ada |
| Tidak ada | **Tipe Katarak** | Tidak ada |

**PEMERIKSAAN TERKAIT LAPISAN AIR MATA**

| | MATA KANAN | MATA KIRI |
|---|---|---|
| <u>TBUT</u><br>- Normal : >10 detik<br>- Mild dry eye : 7-10 detik<br>- Moderate dry eye : 4-6 detik<br>- Severe dry eye : ≤ 3 detik | | |
| <u>OCULAR STAINING</u><br>- Normal : Grade 0-1<br>- Mild dry eye : Grade I-II<br>- Moderate dry eye : Grade II-III<br>- Severe dry eye : Grade IV-V<br>  | | |
| <u>Schrimer Test</u><br>- Normal : 15 mm<br>- Mild Dry eye : 9-14 mm.<br>- Moderate Dry eye : 4 – 8 mm.<br>- Severe Dry eye : < 4 mm. | | |

# LAMPIRAN 4: DATA SAMPEL PENELITIAN

| No. | Nama | Umur | Penyakit Sistemik | Jenis Kelamin | Jenis Sampel | | Visus (Snellen Decimal) | | OSDI | | Schirmer 1 | | | | TBUT | | | | Derajat Ocular Staining | | | | Derajat Dry Eye Berdasarkan TBUT (Normal = 0, Mild = 1, Moderate = 2, Severe = 3) | | | | Derajat Dry Eye Berdasarkan OSDI (Normal = 0, Mild = 1, Moderate = 2, Severe = 3) | | Nilai Vit. D3 Air Mata (Nilai <30 = Hipovitaminosis, Nilai 30-100 = Normal, >100 = Hipervitaminosis) Intepretasi 1 = Hipovitaminosis, 2 = Normal, 3 = Hipervitaminosis | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | Monoterapi | Kombinasi Terapi | OD | OS | Sebelum | Sesudah | Sebelum OD | Sebelum OS | Sesudah OD | Sesudah OS | Sebelum OD | Sebelum OS | Sesudah OD | Sesudah OS | Sebelum OD | Sebelum OS | Sesudah OD | Sesudah OS | Derajat OD Sebelum | Derajat OS Sebelum | Derajat OD Sesudah | Derajat OS Sesudah | Sebelum | Sesudah | Nilai Sebelum OD | Nilai Sebelum OS | Intepretasi Sebelum OD | Intepretasi Sebelum OS | Nilai Sesudah OD | Nilai Sesudah OS | Intepretasi Sesudah OD | Intepretasi Sesudah OS |
| 1 | RT | 63 | Hipertensi | Laki-laki | 2 | 1 | 0.32 | 0.50 | 23 | 0 | 16 | 12.0 | 25 | 25 | 3.0 | 3.0 | 9.0 | 12.0 | 2 | 1 | 1 | 0 | 3 | 3 | 1 | 0 | 2 | 0 | 13.8 | 17.2 | 1 | 1 | 24.4 | 28.8 | 1 | 1 |
| 2 | HR | 28 | - | Laki-laki | 1 | | 0.63 | 0.63 | 14 | 11 | 35 | 30 | 35 | 35 | 9.0 | 8.0 | 14.0 | 13.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 23.4 | 20.6 | 1 | 1 | 21.6 | 36.2 | 1 | 2 |
| 3 | NFR | 32 | - | Perempuan | 2 | 1 | 1.0 | 0.80 | 44 | 11 | 35 | 35 | 35 | 35 | 9.0 | 9.0 | 14.0 | 12.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 0 | 19.6 | 13.9 | 1 | 1 | 45.3 | 37.0 | 2 | 2 |
| 4 | MF | 29 | - | Perempuan | 1 | | 1.0 | 0.80 | 25 | 0 | 35 | 32 | 35 | 35 | 4.0 | 4.0 | 8.0 | 10.0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 2 | 0 | 17.5 | 23.5 | 1 | 1 | 27.9 | 29.1 | 1 | 1 |
| 5 | NA | 32 | - | Laki-laki | 2 | 1 | 1.0 | 0.63 | 19 | 2 | 34 | 34 | 35 | 35 | 8.0 | 9.0 | 13.0 | 14.0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 28.6 | 51.4 | 1 | 2 | 40.0 | 32.2 | 2 | 2 |
| 6 | FGR | 31 | - | Perempuan | 1 | | 0.80 | 1.0 | 13 | 8 | 33 | 35 | 35 | 35 | 6.0 | 7.0 | 9.0 | 10.0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 44.6 | 45.7 | 2 | 2 | 36.8 | 25.4 | 2 | 1 |
| 7 | AA | 47 | - | Perempuan | 2 | 1 | 0.50 | 0.50 | 23 | 6 | 12.0 | 19.0 | 27 | 30 | 3.0 | 3.0 | 7.0 | 7.0 | 1 | 2 | 0 | 1 | 3 | 3 | 1 | 1 | 2 | 0 | 21.7 | 23.3 | 1 | 1 | 39.2 | 31.2 | 2 | 2 |
| 8 | GR | 30 | - | Laki-laki | 1 | | 0.50 | 0.50 | 13 | 4 | 31 | 35 | 35 | 35 | 9.0 | 6.0 | 10.0 | 10.0 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 24.9 | 29.6 | 1 | 1 | 37.3 | 40.3 | 2 | 2 |
| 9 | LA | 56 | - | Perempuan | 2 | 1 | 0.40 | 0.32 | 38 | 8 | 35 | 35 | 35 | 35 | 3.0 | 3.0 | 8.0 | 9.0 | 2 | 1 | 0 | 0 | 3 | 3 | 1 | 1 | 3 | 0 | 60.5 | 23.5 | 2 | 1 | 60.0 | 25.2 | 2 | 1 |
| 10 | MM | 39 | - | Laki-laki | 2 | 1 | 0.50 | 0.40 | 21 | 4 | 35 | 30 | 35 | 35 | 6.0 | 5.0 | 13.0 | 14.0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 23.9 | 28.4 | 1 | 1 | 41.8 | 34.4 | 2 | 2 |
| 11 | FAS | 53 | - | Perempuan | 1 | | 0.50 | 0.40 | 34 | 23 | 35 | 35 | 33 | 35 | 3.0 | 3.0 | 5.0 | 6.0 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 51.9 | 65.7 | 2 | 2 | 36.5 | 39.5 | 2 | 2 |
| 12 | AAM | 40 | - | Perempuan | 2 | 1 | 0.63 | 0.50 | 14 | 6 | 35 | 35 | 35 | 35 | 5.0 | 6.0 | 9.0 | 10.0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 0 | 20.2 | 21.8 | 1 | 1 | 40.5 | 43.2 | 2 | 2 |
| 13 | DIS | 28 | - | Perempuan | 1 | | 0.80 | 0.80 | 19 | 13 | 35 | 35 | 35 | 35 | 5.0 | 7.0 | 8.0 | 9.0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 38.4 | 37.7 | 2 | 2 | 25.7 | 26.1 | 1 | 1 |
| 14 | UMU | 30 | - | Perempuan | 2 | 1 | 0.50 | 0.80 | 21 | 10 | 25 | 35 | 35 | 35 | 5.0 | 5.0 | 11.0 | 11.0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 21.9 | 30.5 | 1 | 2 | 27.3 | 36.2 | 1 | 2 |
| 15 | VO | 40 | - | Laki-laki | 2 | 1 | 0.50 | 0.50 | 14 | 2 | 35 | 35 | 35 | 35 | 5.0 | 5.0 | 7.0 | 10.0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 0 | 20.5 | 23.4 | 1 | 1 | 31.2 | 42.5 | 2 | 2 |
| 16 | PA | 33 | - | Laki-laki | 1 | | 1.0 | 0.80 | 17 | 6 | 25 | 30 | 35 | 35 | 7.0 | 9.0 | 15.0 | 15.0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 33.9 | 26.2 | 2 | 1 | 24.4 | 18.4 | 1 | 1 |
| 17 | AS | 30 | - | Perempuan | 2 | 1 | 0.63 | 0.63 | 17 | 13 | 11.0 | 11.0 | 20 | 21 | 8.0 | 8.0 | 13.0 | 15.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 20.3 | 28.3 | 1 | 1 | 35.3 | 26.1 | 2 | 1 |
| 18 | AT | 42 | - | Laki-laki | 1 | | 0.63 | 0.80 | 23 | 11 | 23 | 35 | 35 | 35 | 4.0 | 5.0 | 12.0 | 10.0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 1 | 2 | 0 | 22.1 | 44.2 | 1 | 2 | 38.1 | 29.9 | 2 | 1 |
| 19 | RA | 27 | - | Perempuan | 2 | 1 | 1.0 | 0.63 | 23 | 6 | 14 | 20 | 35 | 35 | 7.0 | 9.0 | 13.0 | 13.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 27.9 | 40.1 | 1 | 2 | 30.2 | 38.4 | 2 | 2 |
| 20 | AB | 43 | - | Laki-laki | 1 | | 0.40 | 0.40 | 23 | 4 | 7.0 | 10.0 | 23 | 25 | 4.0 | 5.0 | 9.0 | 10.0 | 2 | 2 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 0 | 26.5 | 18.6 | 1 | 1 | 35.5 | 23.5 | 2 | 1 |
| 21 | A | 44 | - | Laki-laki | 2 | 1 | 0.50 | 0.63 | 31 | 10 | 35 | 30 | 35 | 35 | 9.0 | 9.0 | 19.0 | 18.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 20.3 | 26.7 | 1 | 1 | 38.1 | 41.0 | 2 | 2 |
| 22 | ZK | 30 | - | Laki-laki | 2 | 1 | 0.80 | 0.63 | 50 | 23 | 35 | 35 | 35 | 35 | 5.0 | 4.0 | 8.0 | 7.0 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 3 | 2 | 21.2 | 17 | 1 | 1 | 39.1 | 36.5 | 2 | 2 |
| 23 | MS | 33 | - | Laki-laki | 1 | | 1.0 | 1.0 | 13 | 13 | 29 | 35 | 35 | 35 | 9.0 | 9.0 | 17.0 | 18.0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 69.1 | 63.8 | 2 | 2 | 30.0 | 42.8 | 2 | 2 |
| 24 | IPA | 44 | - | Laki-laki | 2 | 1 | 0.50 | 0.40 | 50 | 20 | 35 | 35 | 35 | 35 | 9.0 | 7.0 | 15.0 | 14.0 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 1 | 15.0 | 24.9 | 1 | 1 | 30.5 | 30.0 | 2 | 2 |
| 25 | RPR | 33 | - | Perempuan | 2 | 1 | 1.0 | 1.0 | 23 | 11 | 33 | 35 | 35 | 35 | 5.0 | 5.0 | 16.0 | 15.0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 26.8 | 28.3 | 1 | 1 | 28.4 | 36.0 | 1 | 2 |
| 26 | GC | 36 | - | Perempuan | 1 | | 0.80 | 1.0 | 29 | 10 | 35 | 35 | 35 | 35 | 8.0 | 5.0 | 13.0 | 10.0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 2 | 0 | 33.1 | 26.8 | 2 | 1 | 24.8 | 25.2 | 1 | 1 |
| 27 | PA | 64 | Hipertensi | Laki-laki | 2 | 1 | 0.32 | 0.25 | 40 | 21 | 14.0 | 14.0 | 25 | 20 | 2.0 | 2.0 | 6.0 | 6.0 | 3 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 3 | 1 | 43.9 | 22.6 | 2 | 1 | 35.6 | 39.0 | 2 | 2 |
| 28 | JNH | 28 | - | Perempuan | 1 | | 1.0 | 1.0 | 31 | 23 | 27 | 20 | 35 | 30 | 7.0 | 6.0 | 8.0 | 9.0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 2 | 2 | 25.3 | 32.7 | 1 | 2 | 23.5 | 40.8 | 1 | 2 |
| 29 | SS | 45 | - | Laki-laki | 2 | 1 | 0.32 | 0.40 | 79 | 11 | 25 | 35 | 30 | 35 | 7.0 | 6.0 | 11.0 | 12.0 | 2 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 3 | 0 | 24.9 | 29.6 | 1 | 1 | 39.5 | 37.1 | 2 | 2 |
| 30 | F | 46 | - | Laki-laki | 1 | | 0.40 | 0.50 | 35 | 21 | 10.0 | 21.0 | 15.0 | 25 | 3.0 | 3.0 | 6.0 | 10.0 | 2 | 2 | 1 | 1 | 3 | 3 | 2 | 1 | 3 | 1 | 31.9 | 37.5 | 2 | 2 | 27.7 | 39.7 | 1 | 2 |
| 31 | PN | 45 | - | Perempuan | 2 | 1 | 0.50 | 0.50 | 23 | 8 | 27.0 | 28 | 35 | 35 | 4.0 | 6.0 | 12.0 | 13.0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 23.3 | 31.8 | 1 | 2 | 32.9 | 36.5 | 2 | 2 |

## LAMPIRAN 5: HASIL UJI STATISTIK

### Frequency Table

**Gender**

| | | | Gender | | |
|---|---|---|---|---|---|
| | | | Laki-laki | Perempuan | Total |
| Perlakuan | Monoterapi | Count | 7 | 6 | 13 |
| | | % within Gender | 43,8% | 40,0% | 41,9% |
| | Kombinasi | Count | 9 | 9 | 18 |
| | | % within Gender | 56,3% | 60,0% | 58,1% |
| Total | | Count | 16 | 15 | 31 |
| | | % within Gender | 100,0% | 100,0% | 100,0% |

**Descriptives**

| | Perlakuan | | | Statistic | Std. Error |
|---|---|---|---|---|---|
| OD_pre | Monoterapi | Mean | | 28,9462 | 3,85706 |
| | | 95% Confidence Interval for Mean | Lower Bound | 20,5424 | |
| | | | Upper Bound | 37,3500 | |
| | | 5% Trimmed Mean | | 27,8291 | |
| | | Median | | 21,9000 | |
| | | Variance | | 193,399 | |
| | | Std. Deviation | | 13,90681 | |
| | | Minimum | | 17,50 | |
| | | Maximum | | 60,50 | |
| | | Range | | 43,00 | |
| | | Interquartile Range | | 15,15 | |
| | | Skewness | | 1,561 | ,616 |
| | | Kurtosis | | 1,128 | 1,191 |
| | Kombinasi | Mean | | 30,0778 | 3,02973 |
| | | 95% Confidence Interval for Mean | Lower Bound | 23,6856 | |
| | | | Upper Bound | 36,4699 | |
| | | 5% Trimmed Mean | | 28,8142 | |
| | | Median | | 28,2500 | |
| | | Variance | | 165,227 | |
| | | Std. Deviation | | 12,85405 | |
| | | Minimum | | 13,80 | |
| | | Maximum | | 69,10 | |

| | | | | | |
|---|---|---|---|---|---|
| | | Range | | 55,30 | |
| | | Interquartile Range | | 14,05 | |
| | | Skewness | | 1,627 | ,536 |
| | | Kurtosis | | 4,137 | 1,038 |
| OS_pre | Monoterapi | Mean | | 30,1154 | 3,48758 |
| | | 95% Confidence Interval for Mean | Lower Bound | 22,5166 | |
| | | | Upper Bound | 37,7142 | |
| | | 5% Trimmed Mean | | 28,7782 | |
| | | Median | | 28,3000 | |
| | | Variance | | 158,121 | |
| | | Std. Deviation | | 12,57463 | |
| | | Minimum | | 18,60 | |
| | | Maximum | | 65,70 | |
| | | Range | | 47,10 | |
| | | Interquartile Range | | 6,70 | |
| | | Skewness | | 2,255 | ,616 |
| | | Kurtosis | | 5,408 | 1,191 |
| | Kombinasi | Mean | | 31,2444 | 3,05721 |
| | | 95% Confidence Interval for Mean | Lower Bound | 24,7943 | |
| | | | Upper Bound | 37,6946 | |
| | | 5% Trimmed Mean | | 30,3994 | |
| | | Median | | 27,0500 | |
| | | Variance | | 168,238 | |
| | | Std. Deviation | | 12,97066 | |
| | | Minimum | | 13,90 | |
| | | Maximum | | 63,80 | |
| | | Range | | 49,90 | |
| | | Interquartile Range | | 18,05 | |
| | | Skewness | | 1,007 | ,536 |
| | | Kurtosis | | ,900 | 1,038 |
| OD_post | Monoterapi | Mean | | 37,6385 | 2,24878 |
| | | 95% Confidence Interval for Mean | Lower Bound | 32,7388 | |
| | | | Upper Bound | 42,5381 | |
| | | 5% Trimmed Mean | | 36,9705 | |
| | | Median | | 36,8000 | |
| | | Variance | | 65,741 | |
| | | Std. Deviation | | 8,10808 | |
| | | Minimum | | 27,30 | |
| | | Maximum | | 60,00 | |
| | | Range | | 32,70 | |

| | | | | | |
|---|---|---|---|---|---|
| | | Interquartile Range | | 7,00 | |
| | | Skewness | | 1,658 | ,616 |
| | | Kurtosis | | 4,770 | 1,191 |
| | Kombinasi | Mean | | 30,3167 | 2,28053 |
| | | 95% Confidence Interval for Mean | Lower Bound | 25,5052 | |
| | | | Upper Bound | 35,1282 | |
| | | 5% Trimmed Mean | | 31,0352 | |
| | | Median | | 30,1500 | |
| | | Variance | | 93,614 | |
| | | Std. Deviation | | 9,67545 | |
| | | Minimum | | 2,40 | |
| | | Maximum | | 45,30 | |
| | | Range | | 42,90 | |
| | | Interquartile Range | | 13,40 | |
| | | Skewness | | -1,214 | ,536 |
| | | Kurtosis | | 3,025 | 1,038 |
| OS_post | Monoterapi | Mean | | 32,9846 | 1,92417 |
| | | 95% Confidence Interval for Mean | Lower Bound | 28,7922 | |
| | | | Upper Bound | 37,1770 | |
| | | 5% Trimmed Mean | | 32,9440 | |
| | | Median | | 32,2000 | |
| | | Variance | | 48,131 | |
| | | Std. Deviation | | 6,93768 | |
| | | Minimum | | 23,50 | |
| | | Maximum | | 43,20 | |
| | | Range | | 19,70 | |
| | | Interquartile Range | | 14,15 | |
| | | Skewness | | ,141 | ,616 |
| | | Kurtosis | | -1,462 | 1,191 |
| | Kombinasi | Mean | | 34,8611 | 1,48218 |
| | | 95% Confidence Interval for Mean | Lower Bound | 31,7340 | |
| | | | Upper Bound | 37,9882 | |
| | | 5% Trimmed Mean | | 35,3346 | |
| | | Median | | 36,2000 | |
| | | Variance | | 39,544 | |
| | | Std. Deviation | | 6,28838 | |
| | | Minimum | | 18,40 | |
| | | Maximum | | 42,80 | |
| | | Range | | 24,40 | |

| | | |
|---|---|---|
| Interquartile Range | 9,52 | |
| Skewness | -1,104 | ,536 |
| Kurtosis | 1,307 | 1,038 |

**Ocular Staining OD Sebelum**

| | | | Ocular OD Sebelum | | | |
|---|---|---|---|---|---|---|
| | | | Grade 1 | Grade 2 | Grade 3 | Total |
| Perlakuan | Monoterapi | Count | 9 | 4 | 0 | 13 |
| | | % within Ocular OD Sebelum | 42,9% | 44,4% | 0,0% | 41,9% |
| | Kombinasi | Count | 12 | 5 | 1 | 18 |
| | | % within Ocular OD Sebelum | 57,1% | 55,6% | 100,0% | 58,1% |
| Total | | Count | 21 | 9 | 1 | 31 |
| | | % within Ocular OD Sebelum | 100,0% | 100,0% | 100,0% | 100,0% |

**Ocular Staining OS Sebelum**

| | | | Ocular OS Sebelum | | | |
|---|---|---|---|---|---|---|
| | | | Grade 1 | Grade 2 | Grade 3 | Total |
| Perlakuan | Monoterapi | Count | 8 | 5 | 0 | 13 |
| | | % within Ocular OS Sebelum | 36,4% | 62,5% | 0,0% | 41,9% |
| | Kombinasi | Count | 14 | 3 | 1 | 18 |
| | | % within Ocular OS Sebelum | 63,6% | 37,5% | 100,0% | 58,1% |
| Total | | Count | 22 | 8 | 1 | 31 |
| | | % within Ocular OS Sebelum | 100,0% | 100,0% | 100,0% | 100,0% |

**Ocular Staining OD Sesudah**

| | | | Ocular OD Sebelum | | |
|---|---|---|---|---|---|
| | | | Grade 0 | Grade 1 | Total |
| | onoterapi | Count | 9 | 4 | 13 |
| | | % within Ocular OD Sesudah | 37,5% | 57,1% | 41,9% |
| | ombinasi | Count | 15 | 3 | 18 |

| | | | | | |
|---|---|---|---|---|---|
| | | % within Ocular OD Sesudah | 62,5% | 42,9% | 58,1% |
| Total | | Count | 24 | 7 | 31 |
| | | % within Ocular OD Sesudah | 100,0% | 100,0% | 100,0% |

**Ocular Staining OS Sesudah**

| | | | Ocular OS Sesudah | | |
|---|---|---|---|---|---|
| | | | Grade 0 | Grade 1 | Total |
| Perlakuan | Monoterapi | Count | 9 | 4 | 13 |
| | | % within Ocular OS Sesudah | 36,0% | 66,7% | 41,9% |
| | Kombinasi | Count | 16 | 2 | 18 |
| | | % within Ocular OS Sesudah | 64,0% | 33,3% | 58,1% |
| Total | | Count | 25 | 6 | 31 |
| | | % within Ocular OS Sesudah | 100,0% | 100,0% | 100,0% |

**Derajat TUBT OD Sebelum**

| | | | Derajat TUBT OD Sebelum | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 6 | 5 | 2 | 13 |
| | | % within Derajat TUBT OD Sebelum | 46,2% | 41,7% | 33,3% | 41,9% |
| | Kombinasi | Count | 7 | 7 | 4 | 18 |
| | | % within Derajat TUBT OD Sebelum | 53,8% | 58,3% | 66,7% | 58,1% |
| Total | | Count | 13 | 12 | 6 | 31 |
| | | % within Derajat TUBT OD Sebelum | 100,0% | 100,0% | 100,0% | 100,0% |

**Derajat TUBT OS Sebelum**

| | | | Derajat TUBT OS Sebelum | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 5 | 6 | 2 | 13 |
| | | % within Derajat TUBT OS Sebelum | 45,5% | 42,9% | 33,3% | 41,9% |
| | Kombinasi | Count | 6 | 8 | 4 | 18 |
| | | % within Derajat TUBT OS Sebelum | 54,5% | 57,1% | 66,7% | 58,1% |
| Total | | Count | 11 | 14 | 6 | 31 |
| | | % within Derajat TUBT OS Sebelum | 100,0% | 100,0% | 100,0% | 100,0% |

**Derajat TUBT OD Sesudah**

| | | | Derajat TUBT OD Sesudah | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 4 | 7 | 2 | 13 |
| | | % within Derajat TUBT OD Sesudah | 26,7% | 53,8% | 66,7% | 41,9% |
| | Kombinasi | Count | 11 | 6 | 1 | 18 |
| | | % within Derajat TUBT OD Sesudah | 73,3% | 46,2% | 33,3% | 58,1% |
| Total | | Count | 15 | 13 | 3 | 31 |
| | | % within Derajat TUBT OD Sesudah | 100,0% | 100,0% | 100,0% | 100,0% |

**Derajat TUBT OS Sesudah**

| | | | Derajat TUBT OS Sesudah | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 4 | 8 | 1 | 13 |
| | | % within Derajat TUBT OS Sesudah | 25,0% | 61,5% | 50,0% | 41,9% |
| | Kombinasi | Count | 12 | 5 | 1 | 18 |
| | | % within Derajat TUBT OS Sesudah | 75,0% | 38,5% | 50,0% | 58,1% |
| Total | | Count | 16 | 13 | 2 | 31 |
| | | % within Derajat TUBT OS Sesudah | 100,0% | 100,0% | 100,0% | 100,0% |

**Derajat Dry Eye OD**

| | | | Derajat Dry Eye OD | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 8 | 4 | 1 | 13 |
| | | % within Derajat Dry Eye OD | 57,1% | 40,0% | 14,3% | 41,9% |
| | Kombinasi | Count | 6 | 6 | 6 | 18 |
| | | % within Derajat Dry Eye OD | 42,9% | 60,0% | 85,7% | 58,1% |
| Total | | Count | 14 | 10 | 7 | 31 |
| | | % within Derajat Dry Eye OD | 100,0% | 100,0% | 100,0% | 100,0% |

**Derajat Dry Eye OS**

| | | | Derajat Dry Eye OS | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 8 | 3 | 2 | 13 |
| | | % within Derajat Dry Eye OS | 36,4% | 50,0% | 66,7% | 41,9% |
| | Kombinasi | Count | 14 | 3 | 1 | 18 |
| | | % within Derajat Dry Eye OS | 63,6% | 50,0% | 33,3% | 58,1% |
| Total | | Count | 22 | 6 | 3 | 31 |
| | | % within Derajat Dry Eye OS | 100,0% | 100,0% | 100,0% | 100,0% |

**Vitamin D OD Sebelum**

| | | | Vit D OD Sebelum | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 6 | 7 | 13 |
| | | % within Vit D OD Sebelum | 30,0% | 63,6% | 41,9% |
| | Kombinasi | Count | 14 | 4 | 18 |
| | | % within Vit D OD Sebelum | 70,0% | 36,4% | 58,1% |
| Total | | Count | 20 | 11 | 31 |
| | | % within Vit D OD Sebelum | 100,0% | 100,0% | 100,0% |

**Vitamin D OS Sebelum**

| | | | Vit D OS Sebelum | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 5 | 8 | 13 |
| | | % within Vit D OS Sebelum | 25,0% | 72,7% | 41,9% |
| | Kombinasi | Count | 15 | 3 | 18 |
| | | % within Vit D OS Sebelum | 75,0% | 27,3% | 58,1% |
| Total | | Count | 20 | 11 | 31 |
| | | % within Vit D OS Sebelum | 100,0% | 100,0% | 100,0% |

**Vitamin D OD Sesudah**

| | | | Vit D OD Sesudah | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 3 | 10 | 13 |
| | | % within Vit D OD Sesudah | 30,0% | 47,6% | 41,9% |
| | Kombinasi | Count | 7 | 11 | 18 |
| | | % within Vit D OD Sesudah | 70,0% | 52,4% | 58,1% |
| Total | | Count | 10 | 21 | 31 |
| | | % within Vit D OD Sesudah | 100,0% | 100,0% | 100,0% |

**Vitamin D OS Sesudah**

| | | | Vit D OS Sesudah | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 3 | 10 | 13 |
| | | % within Vit D OS Sesudah | 30,0% | 47,6% | 41,9% |
| | Kombinasi | Count | 7 | 11 | 18 |
| | | % within Vit D OS Sesudah | 70,0% | 52,4% | 58,1% |
| Total | | Count | 10 | 21 | 31 |
| | | % within Vit D OS Sesudah | 100,0% | 100,0% | 100,0% |

**Case Processing Summary**

| | Perlakuan | Cases | | | | | |
|---|---|---|---|---|---|---|---|
| | | Valid | | Missing | | Total | |
| | Perlakuan | N | Percent | N | Percent | N | Percent |
| Age | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| OSDI_pre | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| OSDI_post | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| Schrimer_OD_pre | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| Schrimer_OS_pre | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| Schrimer_OD_post | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| Schrimer_OS_post | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| TBUT_OD_pre | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| TBUT_OS_pre | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| TBUT_OD_post | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |
| TBUT_OS_post | Monoterapi | 13 | 100,0% | 0 | 0,0% | 13 | 100,0% |
| | Kombinasi | 18 | 100,0% | 0 | 0,0% | 18 | 100,0% |

**Descriptives**

| | Perlakuan | | | Statistic | Std. Error |
|---|---|---|---|---|---|
| Age | Monoterapi | Mean | | 35,3846 | 2,24904 |
| | | 95% Confidence Interval for Mean | Lower Bound | 30,4844 | |
| | | | Upper Bound | 40,2849 | |
| | | 5% Trimmed Mean | | 34,8162 | |
| | | Median | | 33,0000 | |
| | | Variance | | 65,756 | |
| | | Std. Deviation | | 8,10903 | |
| | | Minimum | | 28,00 | |
| | | Maximum | | 53,00 | |
| | | Range | | 25,00 | |

| | | | | | |
|---|---|---|---|---|---|
| | | Interquartile Range | | 14,00 | |
| | | Skewness | | 1,045 | ,616 |
| | | Kurtosis | | ,094 | 1,191 |
| | Kombinasi | Mean | | 41,1667 | 2,62871 |
| | | 95% Confidence Interval for Mean | Lower Bound | 35,6206 | |
| | | | Upper Bound | 46,7128 | |
| | | 5% Trimmed Mean | | 40,6852 | |
| | | Median | | 40,0000 | |
| | | Variance | | 124,382 | |
| | | Std. Deviation | | 11,15268 | |
| | | Minimum | | 27,00 | |
| | | Maximum | | 64,00 | |
| | | Range | | 37,00 | |
| | | Interquartile Range | | 14,00 | |
| | | Skewness | | ,802 | ,536 |
| | | Kurtosis | | -,065 | 1,038 |
| OSDI_pre | Monoterapi | Mean | | 22,2308 | 2,25648 |
| | | 95% Confidence Interval for Mean | Lower Bound | 17,3143 | |
| | | | Upper Bound | 27,1472 | |
| | | 5% Trimmed Mean | | 22,0342 | |
| | | Median | | 23,0000 | |
| | | Variance | | 66,192 | |
| | | Std. Deviation | | 8,13587 | |
| | | Minimum | | 13,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 22,00 | |
| | | Interquartile Range | | 16,50 | |
| | | Skewness | | ,297 | ,616 |
| | | Kurtosis | | -1,376 | 1,191 |
| | Kombinasi | Mean | | 30,7222 | 3,94472 |
| | | 95% Confidence Interval for Mean | Lower Bound | 22,3996 | |
| | | | Upper Bound | 39,0449 | |
| | | 5% Trimmed Mean | | 28,9691 | |
| | | Median | | 23,0000 | |
| | | Variance | | 280,095 | |
| | | Std. Deviation | | 16,73603 | |
| | | Minimum | | 14,00 | |
| | | Maximum | | 79,00 | |
| | | Range | | 65,00 | |
| | | Interquartile Range | | 20,50 | |

| | | | | | |
|---|---|---|---|---|---|
| | | Skewness | | 1,591 | ,536 |
| | | Kurtosis | | 2,794 | 1,038 |
| OSDI_post | Monoterapi | Mean | | 11,3077 | 2,03931 |
| | | 95% Confidence Interval for Mean | Lower Bound | 6,8644 | |
| | | | Upper Bound | 15,7510 | |
| | | 5% Trimmed Mean | | 11,2863 | |
| | | Median | | 11,0000 | |
| | | Variance | | 54,064 | |
| | | Std. Deviation | | 7,35283 | |
| | | Minimum | | ,00 | |
| | | Maximum | | 23,00 | |
| | | Range | | 23,00 | |
| | | Interquartile Range | | 12,00 | |
| | | Skewness | | ,422 | ,616 |
| | | Kurtosis | | -,663 | 1,191 |
| | Kombinasi | Mean | | 9,5556 | 1,53227 |
| | | 95% Confidence Interval for Mean | Lower Bound | 6,3227 | |
| | | | Upper Bound | 12,7884 | |
| | | 5% Trimmed Mean | | 9,3395 | |
| | | Median | | 9,0000 | |
| | | Variance | | 42,261 | |
| | | Std. Deviation | | 6,50088 | |
| | | Minimum | | ,00 | |
| | | Maximum | | 23,00 | |
| | | Range | | 23,00 | |
| | | Interquartile Range | | 6,00 | |
| | | Skewness | | ,739 | ,536 |
| | | Kurtosis | | ,057 | 1,038 |
| Schrimer_OD_pre | Monoterapi | Mean | | 28,4615 | 2,72363 |
| | | 95% Confidence Interval for Mean | Lower Bound | 22,5273 | |
| | | | Upper Bound | 34,3958 | |
| | | 5% Trimmed Mean | | 29,1795 | |
| | | Median | | 33,0000 | |
| | | Variance | | 96,436 | |
| | | Std. Deviation | | 9,82018 | |
| | | Minimum | | 7,00 | |
| | | Maximum | | 37,00 | |
| | | Range | | 30,00 | |
| | | Interquartile Range | | 11,00 | |
| | | Skewness | | -1,482 | ,616 |
| | | Kurtosis | | 1,177 | 1,191 |

| | | | | | |
|---|---|---|---|---|---|
| | Kombinasi | Mean | | 27,2778 | 2,24599 |
| | | 95% Confidence Interval for Mean | Lower Bound | 22,5391 | |
| | | | Upper Bound | 32,0164 | |
| | | 5% Trimmed Mean | | 27,7531 | |
| | | Median | | 33,5000 | |
| | | Variance | | 90,801 | |
| | | Std. Deviation | | 9,52894 | |
| | | Minimum | | 11,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 24,00 | |
| | | Interquartile Range | | 19,50 | |
| | | Skewness | | -,753 | ,536 |
| | | Kurtosis | | -1,227 | 1,038 |
| Schrimer_OS_pre | Monoterapi | Mean | | 29,0769 | 2,82947 |
| | | 95% Confidence Interval for Mean | Lower Bound | 22,9120 | |
| | | | Upper Bound | 35,2418 | |
| | | 5% Trimmed Mean | | 30,3632 | |
| | | Median | | 35,0000 | |
| | | Variance | | 104,077 | |
| | | Std. Deviation | | 10,20181 | |
| | | Minimum | | ,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 35,00 | |
| | | Interquartile Range | | 9,50 | |
| | | Skewness | | -2,261 | ,616 |
| | | Kurtosis | | 5,423 | 1,191 |
| | Kombinasi | Mean | | 27,5000 | 2,62374 |
| | | 95% Confidence Interval for Mean | Lower Bound | 21,9644 | |
| | | | Upper Bound | 33,0356 | |
| | | 5% Trimmed Mean | | 28,6111 | |
| | | Median | | 34,5000 | |
| | | Variance | | 123,912 | |
| | | Std. Deviation | | 11,13157 | |
| | | Minimum | | ,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 35,00 | |
| | | Interquartile Range | | 15,25 | |
| | | Skewness | | -1,443 | ,536 |
| | | Kurtosis | | 1,000 | 1,038 |
| ost | Monoterapi | Mean | | 32,3846 | 1,71546 |
| | | | Lower Bound | 28,6470 | |

| | | | | | |
|---|---|---|---|---|---|
| | | 95% Confidence Interval for Mean | Upper Bound | 36,1223 | |
| | | 5% Trimmed Mean | | 33,2051 | |
| | | Median | | 35,0000 | |
| | | Variance | | 38,256 | |
| | | Std. Deviation | | 6,18518 | |
| | | Minimum | | 15,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 20,00 | |
| | | Interquartile Range | | 1,00 | |
| | | Skewness | | -2,456 | ,616 |
| | | Kurtosis | | 5,453 | 1,191 |
| | Kombinasi | Mean | | 32,3333 | 1,12314 |
| | | 95% Confidence Interval for Mean | Lower Bound | 29,9637 | |
| | | | Upper Bound | 34,7029 | |
| | | 5% Trimmed Mean | | 32,8704 | |
| | | Median | | 35,0000 | |
| | | Variance | | 22,706 | |
| | | Std. Deviation | | 4,76507 | |
| | | Minimum | | 20,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 15,00 | |
| | | Interquartile Range | | 5,75 | |
| | | Skewness | | -1,580 | ,536 |
| | | Kurtosis | | 1,333 | 1,038 |
| Schrimer_OS_post | Monoterapi | Mean | | 33,4615 | 1,04154 |
| | | 95% Confidence Interval for Mean | Lower Bound | 31,1922 | |
| | | | Upper Bound | 35,7309 | |
| | | 5% Trimmed Mean | | 33,8462 | |
| | | Median | | 35,0000 | |
| | | Variance | | 14,103 | |
| | | Std. Deviation | | 3,75534 | |
| | | Minimum | | 25,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 10,00 | |
| | | Interquartile Range | | ,00 | |
| | | Skewness | | -2,179 | ,616 |
| | | Kurtosis | | 3,223 | 1,191 |
| | Kombinasi | Mean | | 32,2778 | 1,19587 |
| | | 95% Confidence Interval for Mean | Lower Bound | 29,7547 | |
| | | | Upper Bound | 34,8008 | |

| | | | | | |
|---|---|---|---|---|---|
| | | 5% Trimmed Mean | | 32,8086 | |
| | | Median | | 35,0000 | |
| | | Variance | | 25,742 | |
| | | Std. Deviation | | 5,07364 | |
| | | Minimum | | 20,00 | |
| | | Maximum | | 35,00 | |
| | | Range | | 15,00 | |
| | | Interquartile Range | | 5,00 | |
| | | Skewness | | -1,739 | ,536 |
| | | Kurtosis | | 1,760 | 1,038 |
| TBUT_OD_pre | Monoterapi | Mean | | 6,0000 | ,64051 |
| | | 95% Confidence Interval for Mean | Lower Bound | 4,6044 | |
| | | | Upper Bound | 7,3956 | |
| | | 5% Trimmed Mean | | 6,0000 | |
| | | Median | | 6,0000 | |
| | | Variance | | 5,333 | |
| | | Std. Deviation | | 2,30940 | |
| | | Minimum | | 3,00 | |
| | | Maximum | | 9,00 | |
| | | Range | | 6,00 | |
| | | Interquartile Range | | 4,50 | |
| | | Skewness | | ,096 | ,616 |
| | | Kurtosis | | -1,639 | 1,191 |
| | Kombinasi | Mean | | 5,7778 | ,54566 |
| | | 95% Confidence Interval for Mean | Lower Bound | 4,6265 | |
| | | | Upper Bound | 6,9290 | |
| | | 5% Trimmed Mean | | 5,8086 | |
| | | Median | | 5,0000 | |
| | | Variance | | 5,359 | |
| | | Std. Deviation | | 2,31505 | |
| | | Minimum | | 2,00 | |
| | | Maximum | | 9,00 | |
| | | Range | | 7,00 | |
| | | Interquartile Range | | 4,25 | |
| | | Skewness | | ,048 | ,536 |
| | | Kurtosis | | -1,299 | 1,038 |
| | Monoterapi | Mean | | 5,9231 | ,56001 |
| | | 95% Confidence Interval for Mean | Lower Bound | 4,7029 | |
| | | | Upper Bound | 7,1432 | |
| | | 5% Trimmed Mean | | 5,9145 | |
| | | Median | | 6,0000 | |

| | | | | | |
|---|---|---|---|---|---|
| | | | Variance | 4,077 | |
| | | | Std. Deviation | 2,01914 | |
| | | | Minimum | 3,00 | |
| | | | Maximum | 9,00 | |
| | | | Range | 6,00 | |
| | | | Interquartile Range | 3,00 | |
| | | | Skewness | ,123 | ,616 |
| | | | Kurtosis | -,921 | 1,191 |
| | | Kombinasi | Mean | 5,7778 | ,54566 |
| | | | 95% Confidence Interval for Mean | Lower Bound | 4,6265 |
| | | | | Upper Bound | 6,9290 |
| | | | 5% Trimmed Mean | 5,8086 | |
| | | | Median | 5,5000 | |
| | | | Variance | 5,359 | |
| | | | Std. Deviation | 2,31505 | |
| | | | Minimum | 2,00 | |
| | | | Maximum | 9,00 | |
| | | | Range | 7,00 | |
| | | | Interquartile Range | 4,50 | |
| | | | Skewness | ,112 | ,536 |
| | | | Kurtosis | -1,127 | 1,038 |
| | TBUT_OD_post | Monoterapi | Mean | 10,3077 | 1,00246 |
| | | | 95% Confidence Interval for Mean | Lower Bound | 8,1235 |
| | | | | Upper Bound | 12,4919 |
| | | | 5% Trimmed Mean | 10,2308 | |
| | | | Median | 9,0000 | |
| | | | Variance | 13,064 | |
| | | | Std. Deviation | 3,61443 | |
| | | | Minimum | 5,00 | |
| | | | Maximum | 17,00 | |
| | | | Range | 12,00 | |
| | | | Interquartile Range | 5,50 | |
| | | | Skewness | ,432 | ,616 |
| | | | Kurtosis | -,723 | 1,191 |
| | | Kombinasi | Mean | 11,3333 | ,83235 |
| | | | 95% Confidence Interval for Mean | Lower Bound | 9,5772 |
| | | | | Upper Bound | 13,0894 |
| | | | 5% Trimmed Mean | 11,2037 | |
| | | | Median | 11,5000 | |
| | | | Variance | 12,471 | |
| | | | Std. Deviation | 3,53137 | |

| | | | | | |
|---|---|---|---|---|---|
| | | Minimum | | 6,00 | |
| | | Maximum | | 19,00 | |
| | | Range | | 13,00 | |
| | | Interquartile Range | | 5,25 | |
| | | Skewness | | ,339 | ,536 |
| | | Kurtosis | | -,372 | 1,038 |
| TBUT_OS_post | Monoterapi | Mean | | 9,4615 | ,91017 |
| | | 95% Confidence Interval for Mean | Lower Bound | 7,4785 | |
| | | | Upper Bound | 11,4446 | |
| | | 5% Trimmed Mean | | 9,6239 | |
| | | Median | | 10,0000 | |
| | | Variance | | 10,769 | |
| | | Std. Deviation | | 3,28165 | |
| | | Minimum | | 1,00 | |
| | | Maximum | | 15,00 | |
| | | Range | | 14,00 | |
| | | Interquartile Range | | 1,00 | |
| | | Skewness | | -1,204 | ,616 |
| | | Kurtosis | | 3,644 | 1,191 |
| | Kombinasi | Mean | | 11,7778 | ,74779 |
| | | 95% Confidence Interval for Mean | Lower Bound | 10,2001 | |
| | | | Upper Bound | 13,3555 | |
| | | 5% Trimmed Mean | | 11,7531 | |
| | | Median | | 12,0000 | |
| | | Variance | | 10,065 | |
| | | Std. Deviation | | 3,17260 | |
| | | Minimum | | 6,00 | |
| | | Maximum | | 18,00 | |
| | | Range | | 12,00 | |
| | | Interquartile Range | | 4,25 | |
| | | Skewness | | -,207 | ,536 |
| | | Kurtosis | | -,279 | 1,038 |



**Tests of Normality**

| | Perlakuan | Kolmogorov-Smirnov[a] | | | Shapiro-Wilk | | |
|---|---|---|---|---|---|---|---|
| | | Statistic | df | Sig. | Statistic | df | Sig. |
| | Monoterapi | ,231 | 13 | ,056 | ,856 | 13 | ,034 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | Kombinasi | ,157 | 18 | ,200* | ,902 | 18 | ,063 |
| OSDI_pre | Monoterapi | ,152 | 13 | ,200* | ,902 | 13 | ,143 |
| | Kombinasi | ,289 | 18 | ,000 | ,825 | 18 | ,003 |
| OSDI_post | Monoterapi | ,178 | 13 | ,200* | ,928 | 13 | ,322 |
| | Kombinasi | ,190 | 18 | ,086 | ,925 | 18 | ,157 |
| Schrimer_OD_pre | Monoterapi | ,217 | 13 | ,094 | ,771 | 13 | ,003 |
| | Kombinasi | ,281 | 18 | ,001 | ,762 | 18 | ,000 |
| Schrimer_OS_pre | Monoterapi | ,305 | 13 | ,002 | ,659 | 13 | ,000 |
| | Kombinasi | ,276 | 18 | ,001 | ,730 | 18 | ,000 |
| Schrimer_OD_post | Monoterapi | ,433 | 13 | ,000 | ,503 | 13 | ,000 |
| | Kombinasi | ,434 | 18 | ,000 | ,626 | 18 | ,000 |
| Schrimer_OS_post | Monoterapi | ,505 | 13 | ,000 | ,446 | 13 | ,000 |
| | Kombinasi | ,426 | 18 | ,000 | ,603 | 18 | ,000 |
| TBUT_OD_pre | Monoterapi | ,191 | 13 | ,200* | ,888 | 13 | ,090 |
| | Kombinasi | ,187 | 18 | ,096 | ,914 | 18 | ,102 |
| TBUT_OS_pre | Monoterapi | ,138 | 13 | ,200* | ,942 | 13 | ,489 |
| | Kombinasi | ,140 | 18 | ,200* | ,917 | 18 | ,116 |
| TBUT_OD_post | Monoterapi | ,180 | 13 | ,200* | ,952 | 13 | ,631 |
| | Kombinasi | ,135 | 18 | ,200* | ,959 | 18 | ,585 |
| TBUT_OS_post | Monoterapi | ,290 | 13 | ,004 | ,812 | 13 | ,009 |
| | Kombinasi | ,139 | 18 | ,200* | ,965 | 18 | ,700 |

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

**Perlakuan * Gender**

| | | | Gender | | |
|---|---|---|---|---|---|
| | | | Laki-laki | Perempuan | Total |
| Perlakuan | Monoterapi | Count | 7 | 6 | 13 |
| | | % within Gender | 43,8% | 40,0% | 41,9% |
| | Kombinasi | Count | 9 | 9 | 18 |
| | | % within Gender | 56,3% | 60,0% | 58,1% |
| Total | | Count | 16 | 15 | 31 |
| | | % within Gender | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|---|---|---|---|---|---|
| Pearson Chi-Square | ,045[a] | 1 | ,833 | | |
| Continuity Correction[b] | ,000 | 1 | 1,000 | | |
| Likelihood Ratio | ,045 | 1 | ,832 | | |
| Fisher's Exact Test | | | | 0,031 | ,561 |
| Linear-by-Linear Association | ,043 | 1 | ,835 | | |
| N of Valid Cases | 31 | | | | |

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 6,29.

b. Computed only for a 2x2 table

**Crosstab**

| | | | DerajatTUBT_OD_pre | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 6 | 5 | 2 | 13 |
| | | % within DerajatTUBT_OD_pre | 46,2% | 41,7% | 33,3% | 41,9% |
| | Kombinasi | Count | 7 | 7 | 4 | 18 |
| | | % within DerajatTUBT_OD_pre | 53,8% | 58,3% | 66,7% | 58,1% |
| Total | | Count | 13 | 12 | 6 | 31 |
| | | % within DerajatTUBT_OD_pre | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | ,278[a] | 2 | ,027 |
| Likelihood Ratio | ,282 | 2 | ,029 |
| Linear-by-Linear Association | ,259 | 1 | ,611 |
| N of Valid Cases | 31 | | |

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 2,52.

**Crosstab**

| | | | DerajatTUBT_OS_pre | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 5 | 6 | 2 | 13 |
| | | % within DerajatTUBT_OS_pre | 45,5% | 42,9% | 33,3% | 41,9% |
| | Kombinasi | Count | 6 | 8 | 4 | 18 |
| | | % within DerajatTUBT_OS_pre | 54,5% | 57,1% | 66,7% | 58,1% |
| Total | | Count | 11 | 14 | 6 | 31 |
| | | % within DerajatTUBT_OS_pre | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | ,243[a] | 2 | ,048 |
| Likelihood Ratio | ,247 | 2 | ,042 |
| Linear-by-Linear Association | ,200 | 1 | ,655 |
| N of Valid Cases | 31 | | |

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is 2,52.

**Crosstab**

| | | | DerajatTUBT_OD_post | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 4 | 7 | 2 | 13 |
| | | % within DerajatTUBT_OD_post | 26,7% | 53,8% | 66,7% | 41,9% |
| | Kombinasi | Count | 11 | 6 | 1 | 18 |
| | | % within DerajatTUBT_OD_post | 73,3% | 46,2% | 33,3% | 58,1% |
| Total | | Count | 15 | 13 | 3 | 31 |
| | | % within DerajatTUBT_OD_post | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 2,947[a] | 2 | ,029 |
| Likelihood Ratio | 3,004 | 2 | ,033 |
| Linear-by-Linear Association | 2,736 | 1 | ,098 |
| N of Valid Cases | 31 | | |

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 1,26.

**Crosstab**

| | | | DerajatTUBT_OS_post | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 4 | 8 | 1 | 13 |
| | | % within DerajatTUBT_OS_post | 25,0% | 61,5% | 50,0% | 41,9% |
| | Kombinasi | Count | 12 | 5 | 1 | 18 |
| | | % within DerajatTUBT_OS_post | 75,0% | 38,5% | 50,0% | 58,1% |
| Total | | Count | 16 | 13 | 2 | 31 |
| | | % within DerajatTUBT_OS_post | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 3,990[a] | 2 | ,013 |
| Likelihood Ratio | 4,075 | 2 | ,013 |
| Linear-by-Linear Association | 2,805 | 1 | ,094 |
| N of Valid Cases | 31 | | |

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is ,84.

**Crosstab**

| | | | DerajatDry_OD | | | |
|---|---|---|---|---|---|---|
| | | | Mild | Moderate | Severe | Total |
| Perlakuan | Monoterapi | Count | 8 | 4 | 1 | 13 |
| | | % within DerajatDry_OD | 57,1% | 40,0% | 14,3% | 41,9% |
| | Kombinasi | Count | 6 | 6 | 6 | 18 |
| | | % within DerajatDry_OD | 42,9% | 60,0% | 85,7% | 58,1% |
| Total | | Count | 14 | 10 | 7 | 31 |
| | | % within DerajatDry_OD | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 3,543[a] | 2 | ,017 |
| Likelihood Ratio | 3,842 | 2 | ,014 |
| Linear-by-Linear Association | 3,381 | 1 | ,066 |
| N of Valid Cases | 31 | | |

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is 2,94.

**Crosstab**

| | | | DerajatDry_OS | | | |
|---|---|---|---|---|---|---|
| | | | Normal | Mild | Moderate | Total |
| Perlakuan | Monoterapi | Count | 8 | 3 | 2 | 13 |
| | | % within DerajatDry_OS | 36,4% | 50,0% | 66,7% | 41,9% |
| | Kombinasi | Count | 14 | 3 | 1 | 18 |
| | | % within DerajatDry_OS | 63,6% | 50,0% | 33,3% | 58,1% |
| Total | | Count | 22 | 6 | 3 | 31 |
| | | % within DerajatDry_OS | 100,0% | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 1,194[a] | 2 | ,045 |
| Likelihood Ratio | 1,187 | 2 | ,045 |
| Linear-by-Linear Association | 1,152 | 1 | ,283 |
| N of Valid Cases | 31 | | |

a. 4 cells (66,7%) have expected count less than 5. The minimum expected count is 1,26.

**Crosstab**

| | | | VitD_OD_pre | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 6 | 7 | 13 |
| | | % within VitD_OD_pre | 30,0% | 63,6% | 41,9% |
| | Kombinasi | Count | 14 | 4 | 18 |
| | | % within VitD_OD_pre | 70,0% | 36,4% | 58,1% |
| Total | | Count | 20 | 11 | 31 |
| | | % within VitD_OD_pre | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|---|---|---|---|---|---|
| Pearson Chi-Square | 3,298[a] | 1 | ,069 | | |
| Continuity Correction[b] | 2,061 | 1 | ,151 | | |
| Likelihood Ratio | 3,310 | 1 | ,069 | | |
| Fisher's Exact Test | | | | ,012 | ,076 |
| Linear-by-Linear Association | 3,191 | 1 | ,074 | | |
| N of Valid Cases | 31 | | | | |

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,61.

b. Computed only for a 2x2 table

**Crosstab**

| | | | VitD_OS_pre | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 5 | 8 | 13 |
| | | % within VitD_OS_pre | 25,0% | 72,7% | 41,9% |
| | Kombinasi | Count | 15 | 3 | 18 |
| | | % within VitD_OS_pre | 75,0% | 27,3% | 58,1% |
| Total | | Count | 20 | 11 | 31 |
| | | % within VitD_OS_pre | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|---|---|---|---|---|---|
| uare | 6,639[a] | 1 | ,010 | | |

| | | | | | |
|---|---|---|---|---|---|
| Continuity Correction[b] | 4,824 | 1 | ,028 | | |
| Likelihood Ratio | 6,781 | 1 | ,009 | | |
| Fisher's Exact Test | | | | ,021 | ,014 |
| Linear-by-Linear Association | 6,425 | 1 | ,011 | | |
| N of Valid Cases | 31 | | | | |

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,61.

b. Computed only for a 2x2 table

**Crosstab**

| | | | VitD_OD_post | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 3 | 10 | 13 |
| | | % within VitD_OD_post | 30,0% | 47,6% | 41,9% |
| | Kombinasi | Count | 7 | 11 | 18 |
| | | % within VitD_OD_post | 70,0% | 52,4% | 58,1% |
| Total | | Count | 10 | 21 | 31 |
| | | % within VitD_OD_post | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|---|---|---|---|---|---|
| Pearson Chi-Square | ,864[a] | 1 | ,353 | | |
| Continuity Correction[b] | ,292 | 1 | ,589 | | |
| Likelihood Ratio | ,883 | 1 | ,347 | | |
| Fisher's Exact Test | | | | ,045 | ,297 |
| Linear-by-Linear Association | ,836 | 1 | ,361 | | |
| N of Valid Cases | 31 | | | | |

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,19.

b. Computed only for a 2x2 table

**Crosstab**

| | | | VitD_OS_post | | |
|---|---|---|---|---|---|
| | | | Hipovitaminosis | Normal | Total |
| Perlakuan | Monoterapi | Count | 3 | 10 | 13 |
| | | % within VitD_OS_post | 30,0% | 47,6% | 41,9% |
| | Kombinasi | Count | 7 | 11 | 18 |
| | | % within VitD_OS_post | 70,0% | 52,4% | 58,1% |
| Total | | Count | 10 | 21 | 31 |
| | | % within VitD_OS_post | 100,0% | 100,0% | 100,0% |

**Chi-Square Tests**

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|---|---|---|---|---|---|
| Pearson Chi-Square | ,864[a] | 1 | ,353 | | |
| Continuity Correction[b] | ,292 | 1 | ,589 | | |
| Likelihood Ratio | ,883 | 1 | ,347 | | |
| Fisher's Exact Test | | | | ,042 | ,297 |
| Linear-by-Linear Association | ,836 | 1 | ,361 | | |
| N of Valid Cases | 31 | | | | |

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,19.

b. Computed only for a 2x2 table

**Independent Samples Test**

| | | Levene's Test for Equality of Variances | | t-test for Equality of Means | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | 95% Confidence Interval of the Difference | |
| | | F | Sig. | t | df | Sig. (2-tailed) | Mean Difference | Std. Error Difference | Lower | Upper |
| Age | Equal variances assumed | 1,021 | ,321 | -1,588 | 29 | ,123 | -5,78205 | 3,64201 | -13,23079 | 1,66669 |
| | Equal es d | | | -1,671 | 28,991 | ,105 | -5,78205 | 3,45953 | -12,85767 | 1,29357 |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| OSDI_pre | Equal variances assumed | 4,355 | ,046 | -1,686 | 29 | ,103 | -8,49145 | 5,03793 | -18,79517 | 1,81226 |
| | Equal variances not assumed | | | -1,869 | 26,002 | ,073 | -8,49145 | 4,54451 | -17,83279 | ,84989 |
| OSDI_post | Equal variances assumed | ,215 | ,646 | ,701 | 29 | ,489 | 1,75214 | 2,49915 | -3,35920 | 6,86347 |
| | Equal variances not assumed | | | ,687 | 23,979 | ,499 | 1,75214 | 2,55081 | -3,51272 | 7,01699 |
| Schrimer_OD_pre | Equal variances assumed | ,158 | ,694 | ,337 | 29 | ,739 | 1,18376 | 3,51256 | -6,00023 | 8,36775 |
| | Equal variances not assumed | | | ,335 | 25,535 | ,740 | 1,18376 | 3,53024 | -6,07920 | 8,44672 |
| Schrimer_OS_pre | Equal variances assumed | ,501 | ,485 | ,403 | 29 | ,690 | 1,57692 | 3,91514 | -6,43044 | 9,58429 |
| | Equal variances not assumed | | | ,409 | 27,274 | ,686 | 1,57692 | 3,85874 | -6,33684 | 9,49069 |
| Schrimer_OD_post | Equal variances assumed | ,043 | ,836 | ,026 | 29 | ,979 | ,05128 | 1,96482 | -3,96722 | 4,06978 |
| | Equal variances not assumed | | | ,025 | 21,681 | ,980 | ,05128 | 2,05042 | -4,20467 | 4,30724 |
| Schrimer_OS | Equal variances | 1,607 | ,215 | ,711 | 29 | ,483 | 1,18376 | 1,66499 | -2,22153 | 4,58905 |
| | es | | | ,746 | 28,963 | ,461 | 1,18376 | 1,58585 | -2,05984 | 4,42736 |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| TBUT_OD_pre | Equal variances assumed | ,004 | ,950 | ,264 | 29 | ,794 | ,22222 | ,84177 | -1,49940 | 1,94384 |
| | Equal variances not assumed | | | ,264 | 26,052 | ,794 | ,22222 | ,84143 | -1,50719 | 1,95164 |
| TBUT_OS_pre | Equal variances assumed | ,376 | ,544 | ,182 | 29 | ,857 | ,14530 | ,79982 | -1,49051 | 1,78111 |
| | Equal variances not assumed | | | ,186 | 27,870 | ,854 | ,14530 | ,78189 | -1,45668 | 1,74727 |
| TBUT_OD_post | Equal variances assumed | ,024 | ,879 | -,790 | 29 | ,436 | -1,02564 | 1,29793 | -3,68021 | 1,62892 |
| | Equal variances not assumed | | | -,787 | 25,645 | ,438 | -1,02564 | 1,30297 | -3,70575 | 1,65446 |
| TBUT_OS_post | Equal variances assumed | ,426 | ,519 | -1,977 | 29 | ,058 | -2,31624 | 1,17134 | -4,71189 | ,07941 |
| | Equal variances not assumed | | | -1,966 | 25,475 | ,060 | -2,31624 | 1,17796 | -4,74000 | ,10752 |

## Mann-Whitney Test

**Ranks**

| | Perlakuan | N | Mean Rank | Sum of Ranks |
|---|---|---|---|---|
| Age | Monoterapi | 13 | 13,12 | 170,50 |
| | Kombinasi | 18 | 18,08 | 325,50 |
| | Total | 31 | | |
| OSDI_pre | Monoterapi | 13 | 13,27 | 172,50 |
| | Kombinasi | 18 | 17,97 | 323,50 |
| | Total | 31 | | |
| OSDI_post | Monoterapi | 13 | 17,50 | 227,50 |
| | Kombinasi | 18 | 14,92 | 268,50 |
| | Total | 31 | | |
| Schrimer_OD_pre | Monoterapi | 13 | 16,50 | 214,50 |
| | Kombinasi | 18 | 15,64 | 281,50 |
| | Total | 31 | | |
| Schrimer_OS_pre | Monoterapi | 13 | 16,73 | 217,50 |
| | Kombinasi | 18 | 15,47 | 278,50 |
| | Total | 31 | | |
| Schrimer_OD_post | Monoterapi | 13 | 16,31 | 212,00 |
| | Kombinasi | 18 | 15,78 | 284,00 |
| | Total | 31 | | |
| Schrimer_OS_post | Monoterapi | 13 | 17,12 | 222,50 |
| | Kombinasi | 18 | 15,19 | 273,50 |
| | Total | 31 | | |
| TBUT_OD_pre | Monoterapi | 13 | 16,42 | 213,50 |
| | Kombinasi | 18 | 15,69 | 282,50 |
| | Total | 31 | | |
| TBUT_OS_pre | Monoterapi | 13 | 16,38 | 213,00 |
| | Kombinasi | 18 | 15,72 | 283,00 |
| | Total | 31 | | |
| TBUT_OD_post | Monoterapi | 13 | 14,69 | 191,00 |
| | Kombinasi | 18 | 16,94 | 305,00 |
| | Total | 31 | | |
| TBUT_OS_post | Monoterapi | 13 | 12,35 | 160,50 |
| | Kombinasi | 18 | 18,64 | 335,50 |
| | Total | 31 | | |

**Paired Samples Statistics**

| | | | Statistic | Bootstrap[a] Bias | Std. Error | 95% Confidence Interval Lower | Upper |
|---|---|---|---|---|---|---|---|
| Pair 1 | Schrimer_OD_pre | Mean | 27,7742 | ,0328 | 1,6723 | 24,3557 | 30,8701 |
| | | N | 31 | | | | |
| | | Std. Deviation | 9,50687 | -,21593 | 1,05641 | 6,81387 | 11,00195 |
| | | Std. Error Mean | 1,70748 | | | | |
| | Schrimer_OD_post | Mean | 32,3548 | ,0141 | ,9538 | 30,3548 | 34,0323 |
| | | N | 31 | | | | |
| | | Std. Deviation | 5,30753 | -,21765 | 1,06418 | 2,87817 | 7,03832 |
| | | Std. Error Mean | ,95326 | | | | |
| Pair 2 | Schrimer_OS_pre | Mean | 28,1613 | ,0504 | 1,8429 | 24,4202 | 31,6774 |
| | | N | 31 | | | | |
| | | Std. Deviation | 10,60533 | -,39880 | 1,78844 | 6,35619 | 13,38564 |
| | | Std. Error Mean | 1,90477 | | | | |
| | Schrimer_OS_post | Mean | 32,7742 | ,0367 | ,7925 | 31,1290 | 34,1935 |
| | | N | 31 | | | | |
| | | Std. Deviation | 4,53659 | -,19928 | ,81009 | 2,61304 | 5,73729 |
| | | Std. Error Mean | ,81480 | | | | |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Correlations**

| | | N | Correlation | Sig. | Bootstrap for Correlation[a] Bias | Std. Error | 95% Confidence Interval Lower | Upper |
|---|---|---|---|---|---|---|---|---|
| Pair 1 | Schrimer_OD_pre & Schrimer_OD_post | 31 | ,818 | ,000 | -,004 | ,085 | ,613 | ,934 |
| Pair 2 | Schrimer_OS_pre & ner_OS | 31 | ,858 | ,000 | -,014 | ,084 | ,641 | ,952 |

ise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Test**

| | | Paired Differences | | | | | t | df | Sig. (2-tailed) |
|---|---|---|---|---|---|---|---|---|---|
| | | Mean | Std. Deviation | Std. Error Mean | 95% Confidence Interval of the Difference | | | | |
| | | | | | Lower | Upper | | | |
| Pair 1 | Schrimer_OD_pre - Schrimer_OD_post | -4,58065 | 6,00430 | 1,07840 | -6,78304 | -2,37825 | -4,248 | 30 | ,000 |
| Pair 2 | Schrimer_OS_pre - Schrimer_OS_post | -4,61290 | 7,10717 | 1,27648 | -7,21983 | -2,00597 | -3,614 | 30 | ,001 |

**Bootstrap for Paired Samples Test**

| | | Mean | Bootstrap[a] | | | | |
|---|---|---|---|---|---|---|---|
| | | | Bias | Std. Error | Sig. (2-tailed) | 95% Confidence Interval | |
| | | | | | | Lower | Upper |
| Pair 1 | Schrimer_OD_pre - Schrimer_OD_post | -4,58065 | ,01871 | 1,06961 | ,003 | -6,77337 | -2,45161 |
| Pair 2 | Schrimer_OS_pre - Schrimer_OS_post | -4,61290 | ,01365 | 1,23769 | ,010 | -7,16047 | -2,29114 |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Statistics**

| | | Statistic | Bootstrap[a] | | | |
|---|---|---|---|---|---|---|
| | | | Bias | Std. Error | 95% Confidence Interval | |
| | | | | | Lower | Upper |
| _OD | Mean | 5,8710 | -,0038 | ,3978 | 5,0653 | 6,6774 |
| | N | 31 | | | | |
| | Std. Deviation | 2,27658 | -,04198 | ,17365 | 1,89233 | 2,57824 |
| | Std. Error Mean | ,40889 | | | | |
| | Mean | 10,9032 | -,0241 | ,6056 | 9,7097 | 12,0960 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | TBUT_OD_post | N | 31 | | | | |
| | | Std. Deviation | 3,54358 | -,09145 | ,36658 | 2,78958 | 4,17442 |
| | | Std. Error Mean | ,63645 | | | | |
| Pair 2 | TBUT_OS_pre | Mean | 5,8387 | -,0085 | ,3659 | 5,1290 | 6,5161 |
| | | N | 31 | | | | |
| | | Std. Deviation | 2,16174 | -,04331 | ,19104 | 1,72912 | 2,48115 |
| | | Std. Error Mean | ,38826 | | | | |
| | TBUT_OS_post | Mean | 10,8065 | -,0080 | ,5450 | 9,7419 | 11,8710 |
| | | N | 31 | | | | |
| | | Std. Deviation | 3,37065 | -,10988 | ,52070 | 2,30537 | 4,34950 |
| | | Std. Error Mean | ,60539 | | | | |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Correlations**

| | | N | Correlation | Sig. | Bootstrap for Correlation[a] | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | | Bias | Std. Error | 95% Confidence Interval | |
| | | | | | | | Lower | Upper |
| Pair 1 | TBUT_OD_pre & TBUT_OD_post | 31 | ,738 | ,000 | -,002 | ,087 | ,538 | ,875 |
| Pair 2 | TBUT_OS_pre & TBUT_OS_post | 31 | ,421 | ,018 | ,022 | ,232 | -,018 | ,827 |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Test**

| | | Paired Differences | | | | | t | df | Sig. (2-tailed) |
|---|---|---|---|---|---|---|---|---|---|
| | | Mean | Std. Deviation | Std. Error Mean | 95% Confidence Interval of the Difference | | | | |
| | | | | | Lower | Upper | | | |
| Pair 1 | TBUT_OD_pre - TBUT_OD_post | -5,03226 | 2,41501 | ,43375 | -5,91809 | -4,14643 | -11,602 | 30 | ,000 |
| Pair 2 | TBUT_OS_pre - _OS_post | -4,96774 | 3,14626 | ,56508 | -6,12180 | -3,81369 | -8,791 | 30 | ,000 |

**Bootstrap for Paired Samples Test**

| | | | Bootstrap[a] | | | | |
|---|---|---|---|---|---|---|---|
| | | | | | | 95% Confidence Interval | |
| | | Mean | Bias | Std. Error | Sig. (2-tailed) | Lower | Upper |
| Pair 1 | TBUT_OD_pre - TBUT_OD_post | -5,03226 | ,02035 | ,41005 | ,001 | -5,80645 | -4,22581 |
| Pair 2 | TBUT_OS_pre - TBUT_OS_post | -4,96774 | -,00048 | ,49084 | ,001 | -5,87015 | -3,87097 |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Statistics**

| | | | | Bootstrap[a] | | | |
|---|---|---|---|---|---|---|---|
| | | | | | | 95% Confidence Interval | |
| | | | Statistic | Bias | Std. Error | Lower | Upper |
| Pair 1 | VitD_OD_pre | Mean | 1,3548 | ,0020 | ,0810 | 1,1935 | 1,5161 |
| | | N | 31 | | | | |
| | | Std. Deviation | ,48637 | -,00719 | ,02775 | ,40161 | ,50800 |
| | | Std. Error Mean | ,08736 | | | | |
| | VitD_OD_post | Mean | 1,6774 | ,0037 | ,0846 | 1,5161 | 1,8387 |
| | | N | 31 | | | | |
| | | Std. Deviation | ,47519 | -,01074 | ,03657 | ,37388 | ,50800 |
| | | Std. Error Mean | ,08535 | | | | |
| Pair 2 | VitD_OS_pre | Mean | 1,3548 | ,0048 | ,0764 | 1,1935 | 1,5161 |
| | | N | 31 | | | | |
| | | Std. Deviation | ,48637 | -,00545 | ,02559 | ,40161 | ,50800 |
| | | Std. Error Mean | ,08736 | | | | |
| | VitD_OS_post | Mean | 1,6774 | ,0041 | ,0833 | 1,5161 | 1,8387 |
| | | N | 31 | | | | |
| | | Std. Deviation | ,47519 | -,01058 | ,03572 | ,37388 | ,50800 |
| | | Std. Error Mean | ,08535 | | | | |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Correlations**

| | | N | Correlation | Sig. | Bootstrap for Correlation[a] | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | | Bias | Std. Error | 95% Confidence Interval | |
| | | | | | | | Lower | Upper |
| Pair 1 | VitD_OD_pre & VitD_OD_post | 31 | ,223 | ,227 | ,006 | ,167 | -,134 | ,542 |
| Pair 2 | VitD_OS_pre & VitD_OS_post | 31 | ,368 | ,042 | ,002 | ,137 | ,079 | ,626 |

a. Unless otherwise noted, bootstrap results are based on 1000 stratified bootstrap samples

**Paired Samples Test**

| | | Paired Differences | | | | | t | df | Sig. (2-tailed) |
|---|---|---|---|---|---|---|---|---|---|
| | | Mean | Std. Deviation | Std. Error Mean | 95% Confidence Interval of the Difference | | | | |
| | | | | | Lower | Upper | | | |
| Pair 1 | VitD_OD_pre - VitD_OD_post | -,32258 | ,59928 | ,10763 | -,54240 | -,10276 | -2,997 | 30 | ,005 |
| Pair 2 | VitD_OS_pre - VitD_OS_post | -,32258 | ,54081 | ,09713 | -,52095 | -,12421 | -3,321 | 30 | ,002 |

**Bootstrap for Paired Samples Test**

| | | Mean | Bootstrap[a] | | | | |
|---|---|---|---|---|---|---|---|
| | | | Bias | Std. Error | Sig. (2-tailed) | 95% Confidence Interval | |
| | | | | | | Lower | Upper |
| Pair 1 | VitD_OD_pre - VitD_OD_post | -,32258 | -,00165 | ,10260 | ,004 | -,51613 | -,12903 |
| Pair 2 | VitD_OS_pre - VitD_OS_post | -,32258 | ,00071 | ,09333 | ,003 | -,51613 | -,12903 |

ise noted, bootstrap results are based on 1000 stratified bootstrap samples

## LAMPIRAN 6: CURRICULUM VITAE

### *CURRICULUM VITAE*

1. DATA PRIBADI

| | |
|---|---|
| Nama Lengkap | : Muhammad Nur Agung Mappatanga |
| Tempat tanggal lahir | : Pangkajene, 11 Juli 1992 |
| Jenis Kelamin | : Laki-laki |
| Kewarganegaraan | : Warga Negara Indonesia |
| Agama | : Islam |
| Alamat | : Perumahan Puri Taman Sari |
| Email | : dr.muhammadnuragungm@gmail.com |
| Nomor Handphone | : 082347675050 |

2. RIWAYAT PENDIDIKAN

| No | Jenjang Pendidikan | Institusi | Tahun | Tempat |
|---|---|---|---|---|
| 1 | SD | SD Negeri Naru 1 Sape | 2004 | Kab. Bima |
| 2 | SMP | SMP Negeri 1 Sape | 2007 | Kab. Bima |
| 3 | SMA | SMA Negeri 1 Kota Bima | 2010 | Kota Bima |
| 4 | S1 | FK Universitas Muslim Indonesia Makassar | 2011 - 2015 | Makassar |
| 5 | PROFESI | FK Universitas Muslim Indonesia Makassar | 2015 - 2017 | Makassar |
| 6 | PPDS | Departemen Ilmu Kesehatan Mata FK UNHAS | Juli 2020 - Sekarang | Makassar |

3. RIWAYAT PEKERJAAN

| No | Jabatan / Pekerjaan | Periode | Tempat | Instansi |
|---|---|---|---|---|
| 1. | Dokter Umum | Maret 2019 - Juni 2019 | Kab. Bima, Provinsi NTB | RSUD Bima |
| 2. | Dokter Umum | Juli 2019 - 2020 | Kab. Luwu Utara, Prov. Sulawesi Selatan | Puskesmas Masamba |
| | ter Umum | September 2019 - 2020 | Kab. Luwu Utara, Prov. Sulawesi Selatan | RS Hikmah Masamba |
| | ter Umum | 2020 | Kab. Luwu Utara, Prov. Sulawesi Selatan | RSUD Andi Djemma Masamba |